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herpes simplex virus.
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liver function test.
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North London Blood Transfusion Centre.
normal human serum.
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polymerase chain reaction, 
primary hepatocellular carcinoma, 
post transfusion hepatitis, 
radio-immunoas say. 
ribonucleic acid.
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Abstract.
Although the North West Thames Region collects over 200,000 
blood donations each year, less than four cases of post­
transfusion hepatitis B are reported to us annually (Barbara 
and Briggs 1981) presumably reflecting the exclusion of 
approximately 40 donors per annum found to be Hepatitis B 
surface antigen (HBsAg) positive. This study is the first step 
in the analysis of some of the unique data accumulated on 
these HBsAg-positive donations over an eighteen year period.
Routine HBsAg screening of all blood donations became 
mandatory in the U.K. by 1971. Since then, we at the North 
London Blood Transfusion Centre (NLBTC) have monitored as many 
HBsAg-positive donors as possible to obtain epidemiological 
data on HBsAg carriage and the prevalence of other hepatitis B 
virus (HBV) markers, and to examine ways of predicting the 
course of HBV infection, so that we can advise carriers 
concerning their level of infectivity and management of their 
infection in everyday life.
The first section examines the role of HBV in the context of 
blood transfusion. The serological markers of HBV infection 
are described in detail, including viral subtypes and a 
description of mutant and defective strains. The HBV carrier 
state is then briefly described.
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The second section describes current microbiological practices 
in blood transfusion including the present trend towards 
laboratory automation.
The third section details the serological assays available for 
the laboratory detection of HBV infection and an experimental 
evaluation defines the confidence we can place upon assay 
results.
Section four is a preliminary analysis of some of the 
epidemiological data accumulated at the NLBTC over 18 years.
286 HBsAg carriers have been followed up; with particular
■
attention to their HBe antigen and antibody status as the 
markers most relevant to defining infectivity levels. Of the 
35 carriers who were HBeAg-positive at the time of detection,
8 seroconverted from HBe antigen to anti-HBe during the 
follow-up period. HBeAg positivity was shown to be associated 
with raised liver function test (LFT) values. Those who 
seroconverted from HBe antigen to anti-HBe eventually 
developed normal LFT levels. My preliminary observations on 
the duration of HBsAg positivity and also on temporal changes 
in HBsAg titre will form the basis of further work. Although 
complete in itself, this study also serves as a pilot for a 
more comprehensive analysis of the wealth of material still to 
be examined.
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Introduction.
I have been employed as a clinical scientist at the North 
London Blood Transfusion Centre since 1979. During that 
time most of my work has been concerned with the screening 
of blood donations for hepatitis B surface antigen and 
other serological markers of infection with the hepatitis B 
virus. I have also been responsible for keeping a complete 
record of all hepatitis B surface antigen-positive 
donations made at the centre, both at initial recognition 
and later as a result of the examination of confirmatory 
and follow-up samples, often over a long period of time.
The archive material accumulated during the course of my 
work is probably one of the most comprehensive collections 
available worldwide on hepatitis B detection in donated 
blood. This thesis is concerned with the analysis of some 
of the data, together with a description of experimental 
work directed at defining the precision and improving the 
reliability of the testing procedures.
In section 1, I introduce the hepatitis B virus in the 
context of blood transfusion. The section starts with a . 
description of the virus and the disease to which it gives 
rise in man: this is followed by a description of the 
relationship of the hepatitis B virus to other hepatitis 
viruses of man and of certain animals. I then describe all 
the relevant serological markers of infection with the 
hepatitis B virus and show how the virus exhibits different 
subtypes which are useful epidemiologically in following
12
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the spread of infection. The existence of mutants of the 
virus and their probable natural selection to evade the 
immune response after vaccination are discussed. Finally I 
examine the intriguing phenomenon of the existence of a 
carrier state for the virus.
Section 2 contains an outline of the practice of 
transfusion microbiology with particular reference to the 
North London Blood Transfusion Centre where this study was 
carried out. Current techniques are described in some 
detail but these are likely to be improved and replaced in 
future years, therefore I also include a section on the 
role of automation in transfusion microbiology as this is 
one likely direction of future development.
Section 3 describes the assays available for the detection 
and quantitation of the important serological markers of 
HBV infection, and includes an evaluation of the main tests 
used to amass the data employed in this study. A separate 
sub-section summarises the results of a comparative study 
of some of the methods currently available for HBsAg 
screening. Full protocols for the assays used are given as 
appendices.
Section 4 consists of a preliminary analysis of the wealth . 
of epidemiological data accumulated at NLBTC over the last 
18 or more years. I attempt to analyse trends in the donor 
population and pay particular attention to the significance 
to the donor of his infectivity status and also to the 
likely future course of his disease. Other workers have
13
attempted to answer these or similar questions but nowhere 
has there been such an extensive study in terms of the very 
large numbers of donor samples and length of follow-up 
available at NLBTC and the conclusions reached as a result 
of my work add significantly to an understanding of the 
importance to blood transfusion science of the hepatitis B 
virus.
This study is complete in itself but much material remains 
to be examined. The work now completed will therefore serve 
as a pilot for an even more comprehensive analysis' at a 
future date.
14
SECTION 1 ! HEPATITIS AND HEPATITIS VIRUSES
15
1:1 Viral Hepatitis
Viral hepatitis is a systemic disease caused by one of 
several viral agents showing a predilection for the liver.
The clinical picture of hepatitis infection may vary in its 
presentation from inapparent or subclinical infection, 
slight malaise, mild gastrointestinal symptoms and the 
anicteric (not exhibiting jaundice) form of the disease, 
through the acute icteric (with jaundice) illness, severe 
prolonged jaundice and chronic liver disease, to acute 
fulminant hepatitis. (See below).
The acute anicteric form of the disease is characterised by 
malaise, anorexia, nausea and various gastrointestinal 
symptoms. Fever may sometimes occur. Clinically, the liver 
is enlarged and tender, bile is present in the urine and 
biochemical tests show elevation of serum transaminases and 
a transient rise in conjugated bilirubin. The mild nature 
of the clinical manifestations does not preclude 
progression of the hepatic lesions to chronic damage of the 
liver.
In the case of acute icteric hepatitis, the duration of 
symptoms in the pre-icteric phase of the illness varies 
from 1-14 days, but may be longer. Marked anorexia and 
nausea are particularly prominent. Headache, generalised 
myalgia, arthralgia, skin rashes and fever may be present
16
in a number of cases. The predominant presenting symptoms 
are gastrointestinal and toxic in nature. The pre-icteric 
stage progresses to the icteric phase with the appearance 
of dark urine, clay-coloured stools and jaundice. With the 
appearance of jaundice there is usually a rapid improvement 
in symptoms, The jaundice usually deepens during the first 
few days and persists for one or two weeks. The faeces then 
darken again and the jaundice gradually diminishes. 
Recurrence of symptoms and relapses with jaundice may occur 
and sequelae such as subacute hepatitis, chronic hepatitis 
and post-hepatic cirrhosis may follow.
In 1946 Lucke and Mallory introduced the term "fulminant 
hepatitis" to describe a rare form of viral hepatitis which 
was described in the past as "acute yellow atrophy of the 
liver". This form of the disease has a very high mortality 
rate and death often occurs within ten days of onset as a 
result of massive necrosis of the liver. Progressive deep 
jaundice and widespread haemorrhages are a constant 
feature. Stupor, hepatic coma and death usually follow.
During the past two decades, there has been vast progress 
in our understanding of the disease and its causative 
agents. At least four types of viral hepatitis are 
recognised today. These are hepatitis A, hepatitis B, 
hepatitis C, delta hepatitis and non-A, non-B (NANB) 
hepatitis. In addition, sporadic hepatitis may be caused by 
other viruses, for example, yellow fever virus, 
cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes 
simplex virus (HSV), rubella virus and the. enteroviruses.
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A variety of agents have been implicated in the 
transmission of viral hepatitis, the most common being the 
hepatitis A virus (HAV), which causes short incubation 
hepatitis, and the hepatitis B virus (HBV), which is 
associated with long incubation or "serum" hepatitis. The 
empirical separation of acute viral hepatitis into two 
forms (short and long incubation) was the result of ' 
epidemiological data amassed by various workers 1944-1951 
(see A.J.Zuckerman 1972 ) and led to the discovery of the 
"Australia antigen", now recognised as hepatitis B surface 
antigen, in the 1960s by Baruch Blumberg. The actual 
hepatitis B infective virus particle was described by Dane 
et al. in 1970.
In the mid-1970s improved ability to diagnose hepatitis A 
and hepatitis B led to the recognition of the existence of 
yet another type of viral hepatitis, this was designated 
non-A, non-B hepatitis. For a long time, the causative 
agent(s) of both blood-borne and water-borne hepatitis NANB 
were unknown, but recently, in 1989, the Chiron Corporation 
of California USA, announced the discovery and cloning of 
the agent implicated in the transmission of the major 
blood-borne variety of the disease now known as the 
hepatitis C virus (HCV). A viable laboratory screening test 
has been developed and it is now possible to provide blood 
screened for all known agents of viral hepatitis including 
HCV.
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One of the most severe forms of human viral hepatitis 
(especially when associated with chronic hepatitis B) is 
Delta hepatitis, which is one of the more recently 
recognised forms of the disease. The Delta agent (HDV) is a 
defective virus which requires the presence of the 
hepatitis B virus to provide its coat antigen^ HDV is a 
cytopathic virus giving rise to clinical and often severe 
hepatitis.
In blood transfusion, the most reliable method for 
preventing HBV transmission is the screening of blood 
donors for the presence in their serum of the major 
coat-protein of the virus, the hepatitis B surface antigen 
(HBsÀg). This screening is now mandatory for all donor 
blood collected in the U.K. At the North London Blood 
Transfusion Centre, donors who are positive for HBsAg are 
never used for transfusion purposes but are followed up and 
monitored wherever possible to observe the course of their 
infection.
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1:2 The Hepadna Viruses.
The hepadna viruses are hepatotrophic viruses which include 
the human hepatitis virus (HBV), woodchuck hepatitis virus 
(WHV), duck hepatitis virus (DHBV), ground squirrel 
hepatitis virus (GSHV) and more recently, tree squirrel 
hepatitis virus (THBV). All these viruses cause persistent 
virus infection, but only HBV and WHV go on to cause 
chronic active hepatitis. Growing evidence suggests that 
localisation of the HBV antigens on the surface of infected 
hepatocytes represents a target for T-lymphocyte attack, 
causing lysis of autologous hepatocytes. The apparent 
failure to lyse infected hepatocytes, usually accompanied 
by normal liver morphology, is a characteristic attribute 
of the HBV carrier state and is also found in chronic 
carriers of woodchuck hepatitis virus. Chronic WHV 
infection of woodchuck appears to be associated with an 
active form of chronic liver disease and hepatocellular 
carcinoma (HOC). Thus the woodchuck has been an excellent 
animal model of human diseases such as acute and chronic 
viral hepatitis and HOC (Millman et al., 1984; Summers et 
al., 1980a).
The hepadna viruses contain small, circular DNA molecules 
that are partly single-stranded; a DNA polymerase in the 
virion can repair the DNA and make.it double-stranded. In 
some cases the antigens of the non-human hepadna viruses 
within this group partially cross-react with those of HBV,
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especially in the case of the surface and core antigens and 
respective antibody responses (Cote and Gerin, 1983; Gerin, 
1979; Millman et al.. 1982; Siddiqui et al.. 1981) when 
detected in blood or liver tissue. Other viruses in this 
group are morphologically similar to HBV. (See figure 1 ). 
However it is to be noted that the Duck hepatitis virus 
does not possess the X-region in the genome.
Important biological features of the hepadna group of 
viruses include tropism for hepatocytes and very narrow 
host ranges. There is a strong association between 
long-standing hepadna virus infection and the development 
of primary hepatocellular carcinoma in both humans and in 
woodchucks, and viral DNA is found integrated in the 
cellular DNA of many tumours.
Superficially these viruses appear to share some features 
with RNA tumour viruses or retroviruses. Among the common 
features are similarities in genome structure, (see figure 
1) although the nucleic acids in their virions are 
different, i.e. RNA in retroviruses and DNA in hepadna 
viruses, hepadna viral DNA appears to replicate through an 
RNA intermediate using a reverse transcriptase analagous to 
retrovirus replication. Viruses of both groups cause 
persistent infection and viral antigen can be carried in 
the blood for many years. Another similarity between them 
is that viruses of both groups appear to integrate readily 
in cellular DNA . Two well-studied PHC cell lines 
(PLC/PRF/5 and Hep 3B) producing HBsAg have been shown to 
have integrated HBV DNA sequences, integration of HBV DNA
21
when it does occur, is early in infection (Brechot et al.. 
1981), but this integration has not yet been shown to be 
essential to the mechanism of cell transformation, as is 
the case in retroviruses. When exclusively integrated in 
the DNA of infected cells, both hepadna viruses and 
retroviruses may express only the gene for their envelope 
protein.
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Figure 1.
Genomic organisation of the viruses in the hepadna virus group.
HBV = hepatitis B virus, WHV = woodchuck hepatitis virus, GSHV = 
ground squirrel hepatitis virus, DHBV = Pekin duck hepatitis virus. 
C = core gene, S = surface gene P = polymerase gene, X region - 
function not known. Note the partially overlapping regions for 
different genes. This diagram shows the similarity of the genomic 
structure, which mirrors the morphology and also the pathology of 
the different agents in the different hosts. The shading relates to 
the different defined genes. ( see also figure 2. for genetic 
organisation of HBV.)
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Plate 1. Electron Micrograph showing Hepatitis B Virus
particles. 
( y 'i.ooo )
tOOnm
Plate 2. Elctron Micrograph of HBV showing 42 nanometer
particles (HBcAq ) and 22 nanometer particles (HBsAal.
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Plate 3. Electron Micrograph of hepatitis B Virus Particles
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1:3 The Hepatitis B Virus.
The viral aetiology of hepatitis B was suggested in 1908 by 
McDonald but was established by transmission experiments on
I
human volunteers during World War II.(Voegt 1942, Cameron 
1943, MacCallum and Bradley, 1944). Evidence that a 
prolonged carrier state persisting for at least 5 years has 
been provided by Stokes et al. (1954), Neefe et al. (1954) 
and Murray et al. (1955a,b). Murray et al.(1954) recorded 
the case history of a donor in whose blood hepatitis B 
virus was found 135 days after he had donated blood which 
was subseguently incriminated as the cause of hepatitis in 
the recipient. The same donor later developed hepatitis 
himself. Viraemia was demonstrated once again , on this 
occasion 6 months later.
A marker for the presence of the causative agent was first 
discovered in 1964 when Blumberg was investigating 
genetically-determined serum protein polymorphism using the 
Ouchterlony technique of double diffusion in agar gel. He 
found that an antigen from the serum of an Australian 
Aborigine reacted with an antibody in the serum of a 
haemophilia patient who had received multiple transfusions. 
A year later, a technician in Blumberg‘s laboratory 
developed hepatitis and discovered the "Australia Antigen" 
in her own blood and subsequently developed viral 
hepatitis. This occurrence, and the same finding in a 
patient with Down's syndrome who developed hepatitis, 
provided information as to the cause of the disease.
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Subsequent studies on patients with viral hepatitis, 
specifically hepatitis B, confirmed these findings, 
culminating in the clear linkage of HBsAg and hepatitis B 
infection proposed by Prince in 1968.
The actual virus was identified in 1970 by Dane et al., who 
described the morphological forms of the virus (see figures 
3 and 4).
28
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Figure 2.
Genetic organisation of HBV (c.f. figure 1).
The broad arrows surrounding the genome represent the four large 
open reading frames of the (-) strand transcript. The four 
potential coding regions are termed region S (gene S + region 
pre-S), gene C, region P and region X. The two regions 
corresponding to the defined genes S and C are represented by 
crosshatching.
The numbering of the nucleotides on the inner circle corresponds to 
the genome of the aywg subtype.
DIAGRAZ'C'ÏATIC REPRESENTATION OF THE STRUCTURE OF TFIE HEPATITIS B VIRUS-ASSOCIATED
PARTICLES.
HBsAg
DNA.
DMA polymerase
"Dane" Particle - 42 nanometers-
I HBsAg\ V/Vl/LOTHBeAg
Spherical Particle ~ 27 nanometers.
. HBsAg
Filamentous Fom ~ 120 x 22 nanometers,
Figure 3.
Figure 4.
Summary table of HB virus particles
Size Name 1 Comment
Large particles 42nm
diameter
'Dane' 
particle
1 Virion containing 
1 double-stranded DNA
Nucleocapsid core 27nm
diameter
core
1 Contains genome,
1 always enclosed in 
1 Dane particle.
Small particles
18-22nm
diameter
pleomorphic
spherical 
' 22nm
particles'
1 Excess surface Ag. 
1 No DNA present
Long particles 22nm
diameter
tubular
particles
1 ?only present if 
1 Dane particles 
1 present.
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Figure 5.
Diagrammatic representation of the serological responses in (above) 
acute hepatitis B infection and (below) in chronic hepatitis B 
infection. (From Gerety),
1;4 Serological Markers of 
the Hepatitis B Virus.
HBV is an icosahedral particle 42 nm in diameter, enclosing 
a 27 nm electron-dense core (HBcAg) which contains circular 
DNA of low molecular weight.
Two distinct populations of HBcAg have been identified and 
separated by ultracentrifugation on the basis of their 
discrete densities. The heavier HBcAg particles (1.36 
g/cm ) contain DNA and HBV-specific DNA polymerase, while 
the lighter particles are aggregates of surface antigen free 
of DNA.
Specific antibodies to HBcAg develop early during acute 
hepatitis B and persist for long periods in persons 
convalescent from hepatitis B. IgM anti-HBc appears early in 
acute hepatitis B, and IgG anti-HBc appears late in disease 
or during recovery and persists beyond convalescence.
One of the unique features of infection by hepadna viruses 
including HBV is the production of large quantities of 
excess viral coat protein referred to as hepatitis B surface 
antigen (HBsAg). This surface antigen is serologically 
identical to the Australian antigen. Surface antigen 
particles are 18-22 nm in diameter and are seen in both 
spherical and long tubular forms.
The presence of a DNA molecule in the Dane particle was 
first described by Robinson and colleagues (J.Virol 1974).
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The structure of the HBV genome is characteristic and 
unusual. It is a small, circular, partly double-stranded DNA 
molecule with a single-stranded region of variable length. 
The long (-) strand is linear and of a fixed length of about 
3,200 nucleotides. The short (+) strand is of variable . 
length ranging from 50-75% of that of the long strand. The 
position of the 5' ends of the long and short strands and 
that of the 3‘ end of the long strand are fixed, while the 
position of the 3' end of the short strand is variable. The 
maintenance of the circular structure of the genome is 
assured by base pairing of the 5' ends of the two strands 
over a length of about 200 nucleotides. A DNA polymerase is 
associated with the capsid and a protein is covalently . 
linked to the 5' end of the long strand. The activities Of 
these two proteins seem to be related to viral replication. 
Like the other hepadna viruses, HBV is one of the smallest 
mammalian DNA viruses. By employing extensively overlapping 
regions the virus is able to encode much more protein than . 
its genome length would otherwise allow.
Gel electrophoresis of HBsAg reveals two major proteins with 
molecular weights of 25,000 and 28,000 and at least four 
other proteins with molecular weights greater than 25,000. 
All of these proteins appear to be derived from a single 
linear sequence of the HBV DNA genome (see figure 2 ) which 
is designated the S + pre-S + pre-Sl gene (Tiollais and 
Wain-Hobson, 1984.). The two major proteins are the product 
of the S gene, the larger of which is glycosylated.
(Peterson, 1984).
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Alpha-foetoprotein I AFP).
Alpha-foetoprotein is a type of serum protein usually found 
in foetal serum and also in extremely small quantities in 
the serum of a normal adult (less than 10 ng/ml). Raised 
serum concentrations‘of AFP s-up to 500 ng/ml, are seen in 
30-40% of patients with acute viral hepatitis. Highest 
concentrations, up to 5000 ng/ml, are seen in some cases of 
fulminant hepatitis. In 1963 Abelev et al. found AFP in the 
blood of a mouse in which ascites hepatoma had been 
transplanted. Further, in 1964, Tataniov detected it in the 
serum of a patient with hepatoma. In Japan the figures 
showed 77% of hepatoma patients were positive. In the 
strictest sense, there is no more specificity between AFP 
and hepatoma than hepatitis and cirrhosis and abnormal 
pregnancy but in patients with hepatoma, AFP in the serum is 
detected more frequently and in higher concentrations 
(10,000 ng/ml or higher) than in other diseases.
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DNA Polymerase.
I
Kaplan et al. (1973) demonstrated a close correlation 
between the presence of DNA polymerase and the 42 nm virus 
(Dane) particle. The presence of DNA polymerase is therefore 
a useful marker of virus replication. Cappel et al. (1977, 
1978) demonstrated that the presence of DNA polymerase 
activity is often the only marker of hepatitis B virus.
HBsAg was detected in 88% of 178 individuals exposed to 
hepatitis B and another 11% developed core 
antigen-associated polymerase in the absence of surface 
antigen. Hepatitis B was later confirmed in almost all of 
these patients after further serological examination. The 
presence of HBV DNA polymerase also correlates well with the 
presence of HBeAg.
HBV polymerase, although originally described as a 
DNA-dependent DNA polymerase, is now believed to function as 
a reverse transcriptase in the generation of an RNA 
intermediate during viral replication and hence serves as a 
marker of infectivity. The long open reading frame (ORF) of 
the hepatitis B virus genome (see figure 2) codes for a 
polypeptide of 93 kb, and has been assumed to be the gene 
for the viral polymerase. Biochemical assays have been 
developed for the detection of DNA polymerase (see Zuckerman 
and Howard 1979) but are not suitable for the mass screening 
of blood donors.
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Viral DNA.
The presence of viral DNA in the serum can be demonstrated 
by either the polymerase chain reaction PCR (see page 89) or 
by DNA hybridisation techniques. Commercial DNA 
hybridisation will detect picograms of virus material 
present. (PCR may be considered too sensitive). The presence 
of viral DNA may be useful as a marker of infectivity, (see 
page 173) and correletes well with the presence of HBeAg, 
but in reality virtually all transfused HBV infection has 
been accounted for by the presence of HBsAg or anti-HBc ( 
Hoofnagle 1990). It is mainly for this reason we do not use 
viral DNA as a marker of infectivity. Instead we currently 
use HBeAg and and anti-HBe as our infectivity markers (see 
page 173) since the simple one-step RIA in current use (see 
appendix) is free of charge to us and is easy to perform, 
with extemely clean results.
Host Response.
HBsAg.
HBsAg, including the antigenic products of the pre-S region, 
is an early marker of HBV infection. Production of 
antibodies to HBsAg may be delayed but antibodies to pre-S 
antigens may occur quite early in infection.
The discovery of the "Australia antigen", now known as the 
surface antigen (HBsAg), and its association with hepatitis
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(Prince, 1968; Blumberg et al. 1968 ) was an enormous step 
forward in the control of the spread of HBV. The bulk of 
HBsAg is now known to be unassembled viral coat or "surface 
antigen".
Antibodies to the surface antigen and the core antigen are 
known as anti-HBs and anti-HBc respectively. HBsAg is shed 
in excess into the plasma where it may be detected by ■ 
immuno-assays based on the use of anti-HBs. A third antigen, 
HBeAg is a soluble antigen, which can be particle 
associated, and is found only in a proportion of 
HBsAg-positive sera. The major polypeptide in the core of . 
HBV, pl9, carries the antigenic determinants of both HBcAg 
and HBeAg (Takahashi et al. 1981). A series of inhibition 
experiments by monoclonal antibodies suggests that HBcAg has 
a single immunodominant epitope (Waters et al. 1986). The 
DNA sequence of HBV is known and part of it corresponds to 
the amino acid structure of HBsAg (Tiollais et al. 1981).
HBV provides an excellent model for transmission by blood 
transfusion. In addition to its stability, many of the 
infections in adults are subclinical. Because of the length 
of the incubation period, (around three months), there can 
be a prolonged symptomless viraemia which, coupled with the 
carrier state, has made HBV until recently one of the most 
frequent clinical infections transmitted by untested blood 
and blood products.
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Anti-HBs.
Most individuals who recover from hepatitis B infections 
develop anti-HBs (Tedder. 1980); the presence of anti-HBs in 
the plasma protects against re-infection with the same 
strain of virus. (Zuckerman and Howard 1979). Recipients of 
multiple transfusions, such as haemophiliacs, have a high 
frequency of anti-HBs due to the high rate of transfusion 
associated hepatitis (TAH) found in these groups following 
the transfusion of clotting factor concentrates prepared 
from large pools of plasma. (Mollison, Engelfriet and 
Contreras 1987)
Anti-HBc.
Although normally preceded by detectable HBsAg at the onset 
of acute infection, anti-HBc can be demonstrated in most 
persons who have been infected with HBV. It may be first 
detected during the incubation period, sometimes before, but 
generally following the appearance of HBsAg (see figure 5), 
and persists thereafter. High levels of IgM anti-HBc have 
been found in persons undergoing acute infection and have 
been shown to persist for 3-4 months, with replacement by 
IgG anti-HBc. Raised levels of IgM have been observed in 
some carriers, although lower than in acute infection.
Anti-HBc IgM is always present in the serum of HBV carriers 
during the immunoelimination of HBV infected cells during 
both acute and chronic hepatitis B. (Brunetto et.al. 1991).
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Most commercial assays (including our reference test) were 
designed to detect only high levels of anti-HBc IgM in 
patients with acute HBV. Low levels of this antibody are 
specific markers of HBV-induced liver disease when they 
persist in the carrier, therefore a quantitative 
determination is necessary.
In carriers, high titres of IgG anti-HBc may be detected. 
During the recovery phase of an acute hepatitis B infection, 
anti-HBc may be present in the absence of HBsAg and 
anti-HBs. Donations taken at this time may sometimes be 
implicated in transmission of post-transfusion hepatitis 
(PTH) (Hoofnagle et al. 1978). In a small proportion of 
carriers the only serological HBV marker present is 
anti-HBc; some of these individuals may transmit HBV by 
transfusion.
Anti-HBc is present in virtually all patients with chronic 
hepatitis B, and virtually all acute HBsAg cases. Why then 
is not anti-HBc used to diagnose hepatitis B? This is 
because anti-HBc is also present during convalescence and 
long after recovery from HBV infection. To screen blood 
donors for anti-HBc in the absence of HBsAg or anti-HBs has 
been proposed as a means of prevention of the few cases of 
hepatitis B (1%) that occur in recipients of blood 
transfusions despite testing all donor blood for HBsAg. This 
proposal is based on retrospective studies suggesting that 
this serological profile is associated with the transmission 
of hepatitis B to recipients of their blood (Hoofnagle et 
al., 1978). At present however the test is not generally
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used because there is a need to screen all anti-HBc 
positives fôr anti-HBs, since this is an indication of 
immunity (Johnson and McFarlane 1990.). There is a 
significant false-positive rate and care must be taken when 
assessing the significance of samples weakly reactive for 
anti-HBc, especially in the absence of other HBV markers 
(Tedder, Cameron, Wilson-Croome et al. 1980).
Anti-HBc testing is costly and should not replace HBsAg 
testing as this is normally produced earlier in the course 
of infection. In America the test is used as a surrogate 
marker for non-A, non-B hepatitis in conjunction with ALT 
levels.
HBeAg and anti-HBe.
HBeAg is associated with the presence of large numbers of 
infective virus particles and hence is a marker of 
infectivity (see page 37). It was first described in 1972 by 
Magnius and Espmark. Despite extensive studies since that 
time, the relationship between HBeAg and the structure of 
HBV remains unclear. It differs from HBsAg and HBcAg in that 
it is a soluble protein, not virus-bound. It is associated 
with high titres of virus and serological markers of 
hepatitis B virions. Evidence indicates that HBeAg 
correlates with active underlying liver disease. HBeAg is 
encoded by the core gene, possibly with a different promoter 
site, and so is associated with virus replication. It is 
found during acute infection within the period of HBsAg 
positivity (see figure 5). During recovery anti-HBe
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develops. Some chronic carriers who have seroconverted are 
still undergoing active viral replication due to mutation in 
the core gene (see pages 46-47 ). Active viral replication 
is associated with a rise in serum ALT levels due to 
breakdown and damage to the infected hepatocytes (see page 
172). Carriers have HBeAg in their blood initially alongside 
a high level of HBsAg. This phase may last for a variable 
period of time. In the U.K., approximately 20% of 
HBsAg-positive blood donors have HBeAg, (Dow et al. 1980; 
Harrison et al. 1985) compared with one report of 50% in 
Mediterranean countries (Lieberman et al. 1983). Anti-HBe 
eventually replaces HBeAg with an accompanying fall in HBsAg 
levels. Although the risk of transmission of the virus is 
greatly reduced during this second phase, transfusion is 
still very likely to result in HBV infection. Patients who 
are chronically positive for HBsAg can be divided into three 
groups: (A) HBeAg positive, viraemic, and with chronic liver 
disease; (B) HBeAg negative, anti-HBe positive , yet 
viraemic and frequently with more severe and rapidly 
progressive liver disease; and (C) anti-HBe positive without 
viraemia or liver disease. This last group are either from 
group A and have seroconverted or have gone from acute 
hepatitis into a simple carrier state without chronic 
hepatitis developing. From the second group the possibility 
arises that HBeAg may modify the course of the disease.
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1:5 Subtypes of HBV.
i
Levene and Blumberg first recognised in 1969 that HBsAg 
exhibits antigenic heterogeneity. Le Bouvier in 1971 
described three major antigenic determinants. All HBV 
strains have one antigenic determinant in common, designated 
a , which may be of subtype d or y ,the resulting subtypes 
being ad, ay, and in some cases ady (Barbara et al. 1977).
Bancroft in 1972 described additional allelic determinants 
which may be either w or r, which are independent of d and 
y. Thus the
main antigenic subtypes of HBsAg may be summarised in 
simplified form as follows:
Figure 6.
w
adw)
ayw)— >common 
adr)
ayr)— > rare 
ady)— > hybrid
The view presented above is somewhat oversimplified because 
subunits of a as well as a large number of minor antigenic 
subdeterminants have been described.
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Figure 7.
Subtype determinants of HBsAg.
group reactive a
allelic pairs d y
primary subtypes adw, ayw, adr, ayr
additional determinants x, n, j, t, k, q.
Determination of subtypes is useful epidemiologically, 
since their distribution varies geographically and between 
sections of the community. For example the ay subtype is 
predominant among donors from high hepatitis risk regions 
such as the Middle East andi the Mediterranean, but second 
generation immigrants tend to adopt the pattern of the host 
country. Homosexual HBsAg carriers in the U.K. are usually 
of the ad subtype, whilst drug addicts are of the ay 
subtype (Barbara, 1983). Subtype remains the same during 
acute and/or chronic infection in an individual and breeds 
true when transmitted to a susceptible host. Subtype 
antigen elicits antibody to the determinants of that 
specific subtype.
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1:6 Variants of HBV.
During immunisation programmes with approved vaccines on 
contacts of hepatitis B in southern Italy , some of those 
vaccinated have shown signs of infection with a variant 
mutation of the hepatitis B virus, despite production of 
detectable antibody. (Carman et al. 1990)
I
Between 1982 and 1987 infants and other contacts of HBV 
carriers from two regions of Southern Italy were vaccinated 
by both passive and active vaccines. Their immune response 
was monitored and in one group of 1,590, 44 (2.8%) contacts 
of HBV carriers became HBsAg positive despite the presence 
of vaccine-induced antibody. Severe infection occurred in . 
one infant who progressed to the carrier state. Samples of 
the child's DNA revealed that a point mutation from 
guanosine to adenosine at nucleotide position 587 resulted 
in the substitution of arginine for glycine in the highly 
antigenic 'a' determinant of HBsAg, to which a large part 
of the vaccine-induced immunity is directed. This mutation 
was stable as it was present in an isolate from the child 
five years later. The mother's virus was different from 
that of the child, and it is thought that the mutation 
occurred during infection. In this child and in some of the 
other patients the group-specific 'a' determinant was 
partially missing. This must be kept in mind for the design 
of future vaccines since most vaccines are directed towards 
the 'a ' determinant. Hence any mutation in this area may 
result in an "escape mutant" virus which evades
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vaccine-induced immunity, although patients in which the 
variant virus has been found were all vaccinated using 
plasma-derived vaccines. .
A viral infection characterised by the presence of serum 
HBsAg positivity without serum anti-HBc has been 
encountered in Senegal. It is now known that the virus 
implicated in this infection has an identical DNA structure 
to that of HBV and is the result of a different response in 
certain individuals, after HBsAg positivity is lost neither 
anti-HBc nor anti-HBs become detectable. This is considered 
to be a lack of adequate antibody response in the 
individual rather than a genuine case of virus variation 
although the reasons for an apparent "clustering" of cases 
are not explained.
Point mutations in viral sequences have important effects 
on pathogenicity. Further mutations of this kind have been 
observed in a study carried out in London and Athens on 18 
Greek and 3 non-Greek patients positive for HBsAg but 
negative for HBeAg (Carman et al. 1989)
A further study by Kojima et al.1991 descibed fulminant 
hepatitis B associated with precore-defective HBV mutants. 
Direct sequencing of HBV DNA amplified from sera showed 
mutations in 7 out of 8 HBeAg negative patients. Two 
mutations (guanosine to adenosine) wete found in the 
terminal two codons of the pre-core region. The remaining 
patient had the first of these two mutations only. It is 
thought that changes in the nucleotide sequence of the
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pre-core region of HBV are responsible for the failure of 
some patients with continuing viral replication and severe 
liver disease to secrete HBeAg. The first mutation results 
in a translational stop codon at the end of the pre-core 
region that will prevent HBeAg production, because HBeAg is 
a peptide derived by continuous translation from the 
pre-core region through into the core region. The second 
mutation results in a stop codon which may reduce the 
efficient translation of core antigen.
At present the existence of mutant or defective forms of 
the virus does not present a major problem in the context 
of transfusion microbiology in this country as these forms 
appear so far very rare. There is only a problem for 
microbiological screening if the coating antibody used on 
the solid phase is not sufficiently pan-specific to detect 
all mutant or variant forms of HBsAg (see section 3 on 
assays used to detect HBsAg). However consideration may 
have to be given to the inclusion of mutant sequences in 
future vaccines to prevent emergence of escape mutations.
47
1:7 Chronic Carriage of HBsAa.
The term "carrier" in general medical usage indicates an 
infected individual who is able to transmit an agent but 
who lacks manifestations of the disease. In the case of HBV 
however the wide spectrum of hepatic manifestations of HBV 
infection range from normal liver to severe chronic active 
hepatitis and primary hepatocellular carcinoma (PHC). The 
carrier state is more common in males, more likely to 
follow infections acquired in childhood than those acquired 
in adult life, and more likely to occur in patients with 
natural or acquired immune deficiencies. (Zuckerman and 
Howard 1979).
The differentiation between an acute infection and the 
carrier state is of great importance both clinically and 
epidemiologically. A true carrier state for the hepatitis B 
virus has been confirmed by a series of epidemiological and 
clinical findings made by a number of workers, including 
the evaluation of immunopathology observed in liver biopsy 
specimens. The reasons for becoming a carrier are unknown 
but it probably represents a selective failure of the host 
immune system (Tedder. 1980). Although carriers are not 
generally immunoincompetent, infections occurring in 
immunosuppressed persons are known to be more likely to 
progress to a carrier state. The high rate of carriage in 
certain populations, e.g. China and Asia may be explained 
by early infection when the immune system is less 
competent. There also appears to be a genetic
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predisposition towards the carrier state as shown by its 
association with Down's Syndrome.
The individual who exhibits the least symptoms is most at 
risk of becoming a carrier, since he is unable to mount a 
strong immune response to the virus. Most adult infections 
are symptomatic and less likely to become carriers (approx. 
5%). Most adult infections are associated with some form of 
risk behaviour.
The present study is only concerned with investigations 
into some serological aspects of the carrier state.
Evidence that a prolonged carrier state may result in some 
patients has been provided by Stokes et al. (1954), Neefe 
et al. (1954) and Murray et al. (1955a,b). Zuckerman and 
Taylor (1969) demonstrated a well-documented case of 
apparently healthy carriage of hepatitis B antigen for over 
20 years. Giles et al. (1969) tested for HBsAg in serial 
samples of serum obtained before and up to 200 days after 
experimental infection of volunteer children with serum 
containing the MS-2 strain of type B hepatitis. HBsAg was 
detected in all patients after infection with MS-2, often 
before there was any clinical evidence of infection. In 
approximately half of the patients the antigen persisted in 
the serum for 200 days and subseguently for at least 3 
years after infection. With the development of sensitive 
assays for the detection of HBV markers, it has been 
estimated that there are some 2 to 3 hundred million 
carriers in the world (Lever,1987).
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The WHO Expert Committee on Viral Hepatitis, 1977 defines 
the persistent carrier state as the presence of hepatitis B 
surface antigen for 6 months or longer. The hepatocytes of , 
the carrier are chronically infected with HBV and are 
directed by the viral genome to produce excess HBsAg. As a 
result of this chronic infection the carrier circulates 
HBsAg and may manifest a variety of other serological 
markers reflecting the presence of the virus (see earlier 
section on HBV markers). The carrier state is not static, 
the changes which occur with time are similar to the 
changes seen in acute hepatitis B, but over a much longer 
period of time.
Extensive epidemiological surveys have shown that the 
prevalence of HBsAg in apparently healthy persons varies 
from 0.1% to 20%. Europe may be roughly divided into three 
regions (i) northern countries, with a low prevalence of 
about 0.1% or less (ii) central and eastern countries, with 
a 0.1% to 3% prevalence, and (iii) countries bordering the 
Mediterranean, where there is a prevalence of about 5% or 
even higher. The prevalence in North America and Australia 
is 0.1% or less, 3%-5% or higher in Asia, as high as 15 % 
in several tropical countries and as high as 20% in some 
areas, particularly in the Far East, with evidence of 
presence of HBsAg and/or anti-HBs in almost the whole 
population. However, in examining the global distribution 
of HBsAg, it should be noted that standardised tests and 
reagents have not been employed and that full distribution 
has not as yet been completely documented.
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In 1978 Drew et al. put forward the hypothesis that there 
is cross-reactivity between the surface antigen and a 
male-associated antigen. If this is the case, males would 
be more likely to recognise the surface antigen as "self" 
and therefore would persistently carry the antigen. Females 
however, would be more likely to recognise the surface 
antigen as "foreign" and therefore produce surface 
antibody. This may account for the excess of male carriers 
noted by most researchers in this field.
In 1969 Blumberg put forward a genetic hypothesis to 
explain the geographical variation of apparently healthy 
carriers of surface antigen. As a result of family studies 
carried out in Cebu and Bougainville in the Pacific, he 
hypothesised that a gene designated "Au^" is responsible 
for persistence of the surface antigen after infection with 
hepatitis B virus has occurred. This gene is considered to 
be common in tropical areas and rare in temperate zones.
In countries in which infection with hepatitis B virus is 
relatively uncommon, the highest prevalence is found in the
I
20-40 year age group, whereas in those countries where 
infection with hepatitis B virus is relatively common, the 
highest prevalence of HBsAg is observed in children 4-8 
years old, with declining rates among older age groups. The 
decline in antigen carriage rates with age suggests that 
the carrier state is not inevitably life-long. The 
prevalence of surface antibody increases with age.
Hepatitis B e antigen is found more commonly in young
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rather than in adult carriers while the prevalence of 
anti-e appears to increase with age (Ohbayashi et al.. 
1976). These findings suggest that young carriers may be 
the most infective.
Carriers may be divided broadly into two categories of 
infectivity, depending upon the presence in the serum of 
the HBe antigen or its antibody. About 1 in 4 U.K. carriers 
have HBeAg in their serum. It is likely that such persons 
will have recently become carriers and that their blood 
will be highly infectious. More commonly, the carrier will 
have anti-HBe in his or her serum and will be at a later 
stage of the infection. Although anti-HBe carriers are far 
less infectious, the majority are still likely to transmit 
infection by transfusion. For this, reason all 
HBsAg-positive donors must be excluded from giving blood 
for transfusion purposes.
With a volunteer donor population, the most reliable method 
of preventing HBV transmission is the screening of blood 
donors for the presence of HBsAg. It is known that a donor 
can transmit HBV as long as 19 years after having had a 
positive HBsAg test (Zuckerman and Taylor, 1969). It has 
been estimated that carriers clear their HBsAg at a rate of 
about 1.7% per annum (Sampliner et al. 1979; Barbara,1983). 
If and when carriers eventually lose their HBsAg, it is 
usually succeeded by detectable anti-HBs.
More than 70% of apparently healthy British blood donors 
found to be HBsAg-positive gave normal liver function test
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results, as indicated by serum aspartate transaminase (AST) 
and alanine transaminase (ALT) levels,; and were associated 
with anti-HBe positivity. (Barbara et al. 1978). In Dutch 
studies a similar figure was observed. In the remaining 
30%, when the tests remained abnormal over a period of 
time, moderate to severe liver disease was present at 
biopsy in 8 out of 9 cases. Abnormal liver function tests 
(LFTs) (see section 4 for table of normal values) were 
found significantly more often in HBeAg-positive carriers
i
than in anti-HBe-positive carriers (Reesink et al. 1980).
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Liver Disease in Carriers.
Various surveys have found a proportion of asymptomatic 
carriers of HBsAg to have abnormalities of the liver. These 
abnormalities range.in severity from minor changes in the 
nucleus of the cell to severe chronic active hepatitis and 
cirrhosis. The subject has been extensively reviewed by 
Zuckerman (1988) and others. Primary hepatocellular cancer 
is rare in the U.K. Carriers are more at risk of developing 
chronic active hepatitis and cirrhosis. These studies 
suggest that asymptomatic carriers should remain under 
clinical and serological observation to reduce these risks, 
alteration of lifestyle and if necessary medical or 
surgical intervention may be appropriate.
The Link Between HBV and Primary Hepatocellular 
Carcinoma.
In the Par East and in sub-Saharan Africa, chronic 
hepatitis B infection is frequently associated with the 
development of human hepatocellular carcinoma (HCC). This 
association between HBV and HCC makes it one of the most 
frequent fatal malignancies worldwide. Recent estimates 
(Zuckerman, 1983) range from 250,000 to 1,000,000 deaths 
per year from HBV-associated HCC. It is to be hoped that 
HBV vaccination will eventually help to eliminate this 
common cancer of mankind.
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There are many laboratory assays currently on the market 
for the detection of HBsAg in donor blood. The next section 
shows how we screen blood for this marker of HBV infection.
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SECTION 2; THE PRACTICE OF TRANSFUSION MICROBIOLOGY AND A
DESCRIPTION OF THE ASSAYS INVOLVED.
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2;1 Microbiology in Blood Transfusion.
The National Blood Transfusion service was first formed in 
1946 under the provisions of the National Health Service 
Act. The service in the U.K. overall, including the 
Scottish National Blood Transfusion Service now comprises 
19 Regional Transfusion Centres, a Blood Group Reference 
Laboratory and three Blood Products Laboratories.
The North London Blood Transfusion Centre located at 
Colindale North London where this study was prepared, 
supplies specific requirements for many of the London 
teaching hospitals, most of the blood used by general 
hospitals in the region as well as a large percentage of 
the plasma supplied to the Blood Products Laboratories from 
which preparations such as factor VIII and immunoglobulin 
preparations are manufactured
Blood transfusion has progressed sufficiently since the 
first transfusion by James Blundell in 1818, to allow the 
use of component therapy which means that a single donation 
can be split into components such as concentrated red 
cells, washed red cells, frozen red cells, platelets, dried 
plasma and plasma protein fractions and 
hyperimmunoglobulin, and used to treat several patients.
Conrad(1981) stated that the transmission of infection is 
thé most frequent serious complication of transfusion 
therapy. Microbiological screening is therefore a necessity
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in the provision of a safer, low-risk blood supply and in 
the avoidance of some of the unwanted side effects of 
transfusion.
Many of the requirements for microbiological assays in the 
transfusion service are common to other disciplines, but 
transfusion microbiology makes its own special demands. 
Testing must be rapid, to ensure that urgent requests for 
blood can be met at the earliest possible opportunity, but 
must also be of a high degree of sensitivity and applicable 
to hundreds of samples daily. Obviously when large numbers 
of samples are being screened, cost is important, but there 
is also a need for low false-positive rates and simple 
methods using inexpensive and easily maintained equipment.
In addition we need a test which is specific enough not to 
alarm the donor unnecessarily or to waste his valuable unit 
of blood through a mis-diagnosis.
Meeting these requirements may appear impossible but the 
methods employed in the detection of hepatitis B surface 
antigen (HBsAg) in donor blood stand as a model for rapid, 
mass viral diagnosis.
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2:2 The role of automation in transfusion microbiology.
*
As the list of mandatory screening tests and the 
requirements for rapid release of blood increases, the 
chances for making laboratory and clerical errors also 
increases. Chambers et al. reported a 0.3% error rate in 
the throughput of a large biochemistry laboratory. The 
advent of formal product liability highlights the 
obligation to make the blood supply as safe as possible.
One obvious approach is to provide accurate information 
flow and to expand and develop the use of automated systems 
in the laboratory.
The prime target must be the automation of sampling to 
provide specific sample identification with direct input to 
the main computer system. Ideally this should be linked 
with information transfer from the readers at the various 
assay stations to minimise or eliminate manual data flow. 
Results and sample identity can then be centrally 
integrated prior to release of blood or components.
Other aspects of laboratory testing may also be automated 
as appropriate. All screen tests involve several critical 
laboratory steps as follows:
(i) addition of correct sample to specified well
(ii) addition of correct reagent
(iii) procedural steps (various)
(iv) recognition and flagging of reactive samples
(v) correct identification and retrieval of samples
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(vi) appropriate "hold" and donation/component quarantine
(vii) validation and confirmation of reactivity
(viii) re-testing a follow-up sample from the donor.
i
As the numbers of tests performed increase, so the chances 
of error also increase. Deferrals of donors and/or 
donations may be permanent or temporary, thus adding to the 
complexity of information flow. Samples giving 
false-positive reactions, as well as those giving positive 
reactions, must be temporarily deferred pending follow-up. 
An added complication is the need to provide a panel of 
male volunteer donors who are "accredited" as having a 
record of documented "safety", in order that they may be 
boosted with anti-rhesus antibodies to provide a vaccine to 
immunise rhesus-negative mothers against producing 
antibodies to rhesus-positive babies. A variety of test 
results (often non-standard) have to be integrated with 
follow-up testing and/or quarantine, and these data must be 
co-ordinated.
In order to reduce errors of information transcription, 
laboratories should aim to minimise manual data transfer, 
employ systems based on positive sample identification and 
move towards the computerisation of recording results of 
tests analysing these results and transferring the data.
Total automation of testing may be impractical where 
different methodologies are employed. At.NLBTC we process 
up to 1000 Samples, totalling over 4000 tests daily. The 
use of the microtitration system wherever possible and the
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careful use of modern automated samplers can greatly 
increase the rate of throughput. At NLBTC we favour the use 
of sub-sampling from a 96 well microplate filled by an 
automated sampler, because, although automation gives 
precision of information.transfer, it can actually take 
longer than manual sampling where multiple tests are 
performed on any one sample. In centres such as ours,.with 
a large throughput of samples and a wide range of tests, 
one may compromise by making a small number of masterplates 
on an automated sampler and then sub-sampling, thereby 
maintaining most of the benefits of automation but 
achieving the best compromise as regards speed of 
operation. Various machines (e.g. the Costar Transplate) 
can then remove 96 samples at a time in appropriate volumes 
for a variety of simultaneous screen tests. Direct input 
from ELISA readers, RIA gamma counters or HA image 
analysers into the main computer can then integrate with 
the sample-position data fed in from the automated sampler.
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2:3 Summary of routine practice in HBsAq testing at NLBTC 
(For an illustration see figure 8)
Serum samples are supplied for microbiological assays by 
the staff at the donation sessions. Each donation carries 
its own unique identification number. One serum tube is 
supplied per blood unit collected. The caps are removed 
from the tubes manually and all tubes are centrifuged to
i
leave 1.5 cm. of clear serum standing above the blood clot. 
The sample tubes are then placed in aluminium sample 
"blocks" in numerical order and the location of each sample 
is identified on the record sheets generated with the
samples at the donor sessions.
/
The sample tubes are then sub-sampled for the various tests 
performed in the laboratory. For HBsAg testing, 0.1 ml of 
serum is placed simultaneously, using the Costar 
Transplate, into the wells of a commercial EIA assay plate 
coated with guinea-pig anti-HBs. A suitable range of 
positive and negative control sera are included on each 
plate and the plate is incubated for 20 minutes at 40°C 
on a shaker incubator. The plates are then washed on a 
plate washer and 0.1 ml of goat anti-HBs conjugated with 
peroxidase is added to each well of the plate using a 
multi-channel pipette. The plate is then re-incubated on 
the shaker for a further 20 minutes. The plates are then 
re-washed and 0.1 ml of substrate containing hydrogen 
peroxide and TMB chromogen is added to all wells of the
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plate. The plate is allowed to incubate on the bench at 
room temperature for 10 minutes whilst a blue colour 
develops in those wells where HBsAg is present. The 
reaction is stopped by the addition of sulphuric acid which 
turns the blue colour to yellow. The resulting colour is 
read spectrophotometrically. Any samples giving an 
initially positive reaction are re-tested in duplicate.
An attempt is made to specifically neutralise a repeatably 
reactive sample with an anti-serum containing specific 
HBsAg antibody in order to confirm conclusively any 
positive reaction (see appendix 4.j.A positive 
neutralisation test indicates the presence of HBsAg in the 
sample. Failure to neutralise with specific antibody would 
suggest a false positive reaction and the sample is sent to 
the reference laboratory for tests for all HBV markers to 
confirm this.
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Figure 9.
Specimen print—out of HBsAg screening results at NLBTC by the 
Bioelisa EIA assay. The negative controls which determine the 
cut-off O.D.are in positions A.I., A.2, A.3, B.l and B.2. The kit 
positive control is at position B.3 and the BPL 0.25 ng/ml standard 
is in A.4 and the 0.5 ng/ml standard is in B.4. The rest of the 
plate consists of negative donor sera.
Figure 8. Flow-chart to illustrate HBsAa testing procedure at NLBTC.
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When a sample has been identified as HBsAg positive by, 
routine screening it is then tested in duplicate and a 
sample from the actual pack is obtained and tested to 
exclude any clerical 6r labelling errors or 
cross-contamination of the sample. Confirmation of the 
specificity of a positive reaction is essential before the 
donation can be reported as HBsAg positive. Incorrect 
positive reports give rise not only to false information in 
epidemiological studies (Communicable Disease Reports) but 
also to a variety of unnecessary difficulties for donors 
wrongfully designated as HBsAg positive. The positivity is 
therefore validated and confirmed by specific 
neutralisation (see appendix 4.) However, since we have 
changed from SPRIA to EIA, validation is not so clear-cut 
because EIA assays are more prone to the problems of false 
positivity.
The sample is then examined for supplementary tests, some 
of which can be performed in-house but most of which are
i
done at the reference laboratory. These supplementary tests 
consist of anti-HBc, both IgM and total, HBe antigen and 
antibody, surface antigen (and also antibody in the case of 
known previous infections). By performing these 
supplementary tests we are able to see in what phase of 
infection the donor currently is, and by repeatedly 
sampling from the donor at regular intervals we are able to
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monitor the progress of the infection and the donor's 
likely infectivity status.
Categorisation of HBsAa positive donors.
i
1. Anti-HBc negative, HBsAg positive - very early acute 
infection.
2. Anti-HBc positive, anti-HBc IgM positive, HBsAg positive
- some phase of acute infection( up to 6 months).
3. Anti-HBc positive, Anti-HBc IgM negative HBsAg positive
- chronic carrier.
4. HBsAg negative, anti HBc positive anti-HBs positive - 
convalescent/immune.
Within either an acute or chronic infection, the donor 
could be either HBe antigen or antibody positive. In an 
acute infection anti-HBe associates with resolution of the 
infection. In chronic carriage, HBeAg associates with high 
infectivity while anti-HBe associates with lower 
infectivity.
When the results of all these tests are known, the donor is 
counselled and a confirmatory sample is obtained. This 
confirmatory sample is titrated in parallel with the 
original sample. This serves to show that there has been no 
mistake as to the identity of the donor and also to provide 
"kinetic data" i.e. to look for significant changes in the
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titre of HBsAg. If on titration of the confirmatory sample 
the donor appears to be HBsAg negative the results of an 
anti-HBc test (including an anti-HBc IgM) and an anti-HBs 
test will give significant information about his status.
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2:4 Immunoassays in Transfusion Microbiology. 
Evolution of HBsAg testing.
Modern technology has contributed enormously to the 
production of diagnostic assays over the last two decades, 
especially since the development of monoclonal antibodies 
and recombinant or synthetic polypeptides. These have led 
to increasing sensitivity of assays without a 
disproportionate increase in the number of false-positive 
reactions. Increased sensitivity has reduced the 
"diagnostic window" period, between infection and the 
appearance of detectable markers, helping to make the blood 
supply safer.
The evolution of HBsAg testing has reflected some of these 
advances from the early "first generation" assays to the 
present widely used EIA and other recently evolved
I
serological diagnostic assays, such as chemiluminescence 
(see page 83).
In addition, there are now available assays which perform 
direct detection of the viral genome such as the polymerase 
chain reaction (see later description and figure 11) and 
also the ligase chain reaction which also makes use of 
nucleic acid technology. These assays have great potential 
for the future of viral diagnosis.
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Immunodiffusion.
In the early 1960s Blumberg discovered the hepatitis B 
surface antigen (HBsAg) in the serum of an aborigine boy 
(see section 1) using the technique of immunodiffusion. At 
this point mass-screening of blood for transfusion became 
possible, and by 1970 had become a reality. The method 
initially used was that with which HBsAg had first been 
detected, the simple (but relatively insensitive) 
immunodiffusion test (ID). This proved effective because of 
the large amount of excess HBsAg produced by the virus. 
Since HBV is unable to form plaques in tissue culture or 
even to be used in 50% end-point assays in animals, 
virologists have been forced to rely on immunoassays. These 
have been developed to provide rapid and convenient tests 
giving minimal false-positive reactions while avoiding the 
problems that beset cell-culture techniques.
In the technique of immunodiffusion, test serum is 
introduced into wells cut in an agarose gel. The test serum 
is then allowed to diffuse outwards to meet a specific 
antigen or antibody diffusing from another well, an
i
immunoprecipitin line forms at the point where antigen and 
antibody are at optimal concentrations. Experimental 
details may be found in a range of publications (e.g. 
Crowle, 1973).
Though the immunodiffusion test(ID) can be optimised to 
take 12 hours to perform, dramatic advantages were provided 
by the introduction of an electric current through the gel:
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with this technique, an immunoprecipitin reaction can be 
made visible in as little as 2 hours . This method known 
variously as "CIEP" (counter-immuno electrophoresis),
"EIOP" (endimmuno-osmophoresis), "CEP" (cross-over 
electrophoresis),or "CMP" (cross-migration 
electrophoresis), relies on active movement of charged 
antigen in one direction and internal osmotic streaming of 
antibody in the other direction. Since the reactants only 
move towards each other (and not radially) stopping only at 
the precipitin line, this results in a rapid and more 
sensitive assay, with a build-up of precipitin, as the 
assay does not rely only on diffusion.
Reverse passive haemaaalutination.
In 1974 commercial RPHA (reverse passive haemagglutination) 
systems became available. The most widely used in Britain 
was Hepatest (Cayzer et al., 1974) marketed by Wellcome. 
This is still used on a routine basis at NLBTC for the 
follow-up titration of HBsAg positive donors.
Viruses which do not normally produce haemagglutination 
patterns may be induced to do so by the use of red cells
i
coated with antibody to the virus (see figure 10.). This 
antibody may be tagged to fresh erythrocytes or to fixed 
erythrocytes that may then be freeze-dried. The test serum 
is incubated with the antibody-coated erythrocytes, and 
after allowing time for settling, the haemagglutination 
patterns may be read.
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The procedure used routinely until March 1991 supplementary 
to the RIA assay for donor screening at the NLBTC 
consisted of a modified version of the Serodia-HBs test
Ï
(Fujirebio Inc.) and has been described by Barbara (1983). 
In this test the sensitised and unsehsitised red blood 
cells are diluted to 0.1%,instead of the usual 1%, and a 
"spin and slope" technique replaces the usual method of 
allowing the cells to settle in the wells. However, during 
the current study, the original "1%" Hepatest (Wellcome 
Diagnostics)(Cayzer et al..1974) was employed for HBsAg 
quantitation, to allow direct comparability with previous 
results obtained over a number of years.
The principle of the test is that red blood cells can be 
coated with purified antibody. This was originally done by 
Boyden (1951) using tannic acid, giving the so called 
"tanned" red cells. These cells can be agglutinated by very 
small amounts of antigen. Viral agglutination gives rise to 
a "carpet" of cells rather than the "clumping" seen with 
bacterial agglutination.
This type of test had an enormous impact on HBsAg testing 
in the transfusion context, since it lends itself to 
automation and is performed in the microplate format. RPHA 
is more expensive than EIOP which can use in-house 
materials, but is more sensitive and rapid. Use of the test 
is described in detail in appendix 2. The ability to 
freeze-dry the cells affords the advantage of prolonged 
reagent storage. The use of turkey red blood cells 
(nucleated) in Hepatest allows faster settling and fewer
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non-specific cross-reactions with heterophil antibodies 
than mammalian cells. Serodia-HBs (produced by Fujizoki and 
marketed in the U.K. by Mast Laboratories) uses chicken red 
cells in a format similar to Hepatest.
The standard methods of RPHA have been successfully 
modified to reduce costs and increase sensitivity. An 
efficient modification that allows the use of diluted cells 
(and which also increases sensitivity) is to employ the 
method used by haematologists of centrifuging the test in a 
"V"-well microtitration plate to sediment the cells after 
incubation with the diluted test serum and then to incline 
the plate at an angle to observe if the sediment remains 
agglutinated or forms a streak (see plate 4.) This method 
was used at NLBTC using diluted Wellcome Hepatest cells 
(0.1%), and later using Fujizoki Serodia-HBs cells. The 
latter method is still used as a quality assurance for 
donations from previously untested donors.
Classically the red blood cell has been the particle of 
choice for agglutination assays but recently a Japanese 
company (Fujirebio Inc.) have developed gelatin particles 
that mimic the behaviour of erythrocytes in tests requiring 
agglutination procedures. These are currently available for 
anti-HIV and anti-HTLV detection. Coated latex particles 
also offer an agglutination system for antigen detection 
but are often less sensitive than other immunoassays.
( McDonald and Barbara 1988).
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anti-HBs
red blood 
cell
HBsAg
red blood 
cell
Ficmre 10.
Reverse passive haemagglutination assay (RPHA) for HBsAg, 
Antibodies to HBsAg are adsorbed on to the surface of tanned red 
blood cells. Agglutination of these red blood cells occurs in the 
presence of HBsAg.
Plate 4. Close-up of the top right hand corner of a 
microtitration plate showing the four tight buttons of the 
positive control of the 0.1% modified "spin and slope" 
HBsAg haemagglutination assay, and the streaking-effeet of 
negative reactions.
Types of immunoassays.
The more sophisticated assays using plastic microwells, 
beads or paddles/dipsticks as the solid phase have been 
classified by Mortimer et al. (1985) as follows (see figure 
11 A-E):
1. Type I, antiglobulin
2. Type II, competitive
3. Type III, antibody capture
4. Type IV, sandwich
These four basic formats can each be modified in several 
ways. A range of systems can then be used to provide 
"labels" for signalling the specific antigen-antibody 
reactions. Either antigen or antibody may be labelled. The 
most commonly used markers for these types of assay are 
radioactivity, enzymes, lanthanides, chemiluminescence and 
gold labels. The principles of these types of immunoassay 
are illustrated in figure 11.
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Radio immunoas s av.
After haemagglutination, the next stage in HBsAg detection 
was the introduction of the more sensitive RIA assay 
(radio-immunoassay). The early competitive assays took as 
long as six days to perform. Radiolabelled antigen was 
allowed to react with the serum for four days, after which 
free labelled antigen was separated by
chromatoelectrophoresis from labelled antigen bound to 
specific antibody. After staining, the paper strips on 
which separation was effected were dried and passed through 
an automatic strip-scahner for counting. (Walsh, Yalow and 
Berson 1970). These lengthy and cumbersome assays 
eventually gave way to the more convenient solid phase 
"sandwich method" routinely employed until recently at 
NLBTC and described in appendix 1. Linking antibodies to 
particles or surfaces gives a solid-phase reagent. Early 
commercial tests were performed in coated tubes although 
coated beads later became popular. RIA was used at NLBTC 
until March 1991 when an EIA assay was introduced for HBsAg 
testing of all donations.
The principle of the assay for HBsAg is the adsorption of 
viral antibodies on to a solid matrix surface. Various 
materials may be used, for example, disposable plastic 
tubes, plates or beads, made in polystyrene, polypropylene 
or polyvinylchloride. The antibodies immobilised at the 
solid phase provide binding sites for viral antigens in 
the test serum which is subsequently added to these bound
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antibodies. The bound antigen is then detected by the 
125addition of l-labelled antiviral immunoglobulin 6
(IgG).This then forms an antibody-antigen-antibody
"sandwich" attached to the solid phase. The amount of bound 
125 I-labelled antibody is measured with a gamma counter 
and expressed as a ratio of counts-per-minute compared with 
a set of appropriate controls.
The technique used in this study has been described by 
Barbara et al. (i979a) and Cameron et al.(1980) and was 
used routinely in the screening of blood and blood products 
at the NLBTC until March 1991. The microtitre format is 
employed (Barbara 1983) in which strips of light, small 
polystyrene wells ("Remova-strip", Dynatech Laboratories 
Ltd.) are fitted into a polystyrene tray (Dynatech 
Laboratories Ltd.) to form a 96-well, microtitre-format 
plate.
The principle of the "sandwich" type assay is described 
under enzyme immunoassays, (see Figure 11 (E)), and is very 
similar to that of SPRIA, except for the use of a 
radionuclide rather than an enzyme label. Antibody is bound 
to the solid phase (usually a microtitre well). Serum is 
then added and incubated in the well. Excess serum is 
washed away, leaving any antigen bound to the antibody on 
the solid phase. A labelled antibody is then added to form 
the antibody-antigen-antibody "sandwich" if antigen is 
present. When a radioisotope is used as the label, the 
quantity of bound antigen can be measured in a gamma 
counter.
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Enzyme immunoassays.
Recent technological developments in HBV testing include 
the widespread use of monoclonal antibodies particularly in 
the enzyme-linked immunosorbent assay (ELISA), which avoids 
the use of radioactive labels and has a longer shelf-life. 
At NLBTC we currently use an EIA (enzyme immunoassay) 
marketed by Launch Diagnostics which employs polyclonal 
antibodies to HBsAg raised in guinea-pigs and goats. Assay 
time can be shortened by the use of a microplate 
shaker-incubator to only 55 minutes. (For full protocol see 
appendix 3.)
Using enzymes as a label in immunoassays avoids the use of 
controversial radioisotopes. A range of enzymes and 
associated substrates are available e.g. horseradish 
peroxidase with orthophenylene diamine (OPD) or 
tetramethylbenzidine hydrochloride (TUB) as substrate, or 
alkaline phosphatase with p-nitrophenyl phosphate as 
substrate. The resulting colour produced by enzyme and 
substrate as a chromogen can be read photometrically. For 
diagrams of the various types of enzyme immunoassays in 
current use see figure ll(A-E).
"Amplified" EIA systems are available, for example the 
Wellcozyme HBsAg EIA assay. In this system, alkaline 
phosphatase bound to the labelled antibody converts an NADP 
substrate to NAD. When the amplifying agent (alcohol 
dehydrogenase plus diaphorase) is added, NAD is converted
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to NADH in the reaction between alcohol dehydrogenase and 
ethanol. This NADH reacts with iodonitrotetrazolium violet 
to form a coloured complex. NAD formed after the reaction 
can be converted back to NADH; because substrate and enzyme 
are in excess the reaction can cycle and amplify the 
signal.
Chemiluminescence.
The use of a chemiluminescent label in immunoassays, as an 
alternative to radioisotopes, has attracted.considerable 
interest in recent years. Amersham International have 
developed a range of chemiluminescence assays, using 
antibody labelled with horse-radish peroxidase which reacts 
with luminol as a signal-generating reagent. The system can 
be enhanced up to 100-fold by the use of an enhancer such 
as firefly luciferin, p-iodophenol or p-phenylphenol. This 
new labelling system is rapid, light emission is stable and 
sensitivity is improved. (Kricka and Thorpe 1985). 
Unfortunately the company may not have aimed primarily at 
the transfusion service market with these assays: when 
evaluations were performed at NLBTC, the level of 
sensitivity of the HBsAg assay was less than that soon to 
be required by the Blood transfusion Service, i.e. 0.5 
ng/ml. In our own lab we aim to detect a minimum of 0.25 
ng/ml of HBsAg, and ioaany current HBsAg assays will detect 
as little as 0.1 ng HBsAg/ml.
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Constraints of immunoassay systems.
(a).Radioimmunoassay.
125Isotopes with a short half-life such as I have a 
limited shelf-life of only a few weeks, this is the major 
disadvantage of this assay system, as a fresh preparation 
is required in order to achieve consistently high enough 
counts for detection purposes. This fact, and also the need 
to comply with the rigorous requirements of radiation 
protection regulations,.are the main reasons why RIA is 
losing popularity and EIA is becoming increasingly more 
popular in the diagnostic world.
Radiolabels exhibit very low background noise levels 
leading to full realisation of sensitivity. Radioactive 
disintegrations remain unaffected by factors such as pH, 
concentration or temperature, leading to a more robust type 
of assay than EIA with a greater degree of specificity.
i
I feel personally that the decline in popularity of the RIA 
for HBsAg is to be regretted because there is still much 
advantage to be gained in the use of this simple, clean and 
sensitive technique. Product liability constraints forced 
us to abandon this technique due to lack of adequate 
quality control of the solid-phase coating procedure, 
whilst the assay was still of great diagnostic value.
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In immunoradiometric assays the biphasic response or "hook" 
effect^  can be demonstrated at high antigen concentrations. 
(Also referred to as the "prozone." effect.) This introduces 
a problem into the assay of interpretation of results from, 
high concentrations of antigen (as there is an ascending 
and descending curve produced) resulting in counts from the 
solid-phase bound antibody correlating with two different 
concentrations of antigen. At very high concentrations of 
antigen the descending curve can reach a point 
corresponding to the values for very low concentrations.
The sequential addition of reagents together with the 
removal of unreacted species between each reagent addition 
by washing will eliminate the "hook" and replace it with a 
plateau thus removing any ambiguity in the result.
Enzymeimmunoassay.
One of the problems of EIA is non-specific protein binding. 
This can be reduced by the addition of BSA to buffers. Some 
high backgrounds can be due to cross-reactivity or to low 
levels of natural antibodies present in reagents used. BSA 
or other serum proteins can be used to block non-specific 
binding to the solid phase but test samples may contain
i
antibodies to the blocking protein itself. I actually 
observed this phenomenon personally in the use of the 
Biokit HBsAg assay and further purification of the protein 
was required to eliminate it.
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Reaction rates are dependent upon temperature and various 
restraints must be placed upon incubation procedures to 
ensure minimisation of variation, such measures include not
i
stacking plates, the use of heating blocks and the 
selection of suitable lengths of incubation to ensure well 
contents attain the correct temperature, thus avoiding the 
"edge" effect where wells at the edge of the plate 
demonstrate higher readings than those at the centre of the 
plate due to failure of the central wells to attain 
sufficiently high temperatures.
Occasionally the presence of enzyme inhibitors or natural 
enzymes such as peroxidases in the serum may affect the 
readings.
One serious constraint of the EIA system is that it is not 
really technically possible to see an absorbance reading 
greater than 2.0 (although some artifacts may be observed 
practically) since this would constitute 100% absorbance. 
This causes problems in quantitation, as the range of 
measurement is relatively small when compared with that of 
RIA and chemiluminescence assays which have a substantially 
higher upper range of measurement.
The vast majority of commercial HBsAg assays are now EIA 
systems, with the constraints placed upon us by the 
Medicines Inspectorate, the Blood Transfusion Service has 
less choice as to the type of assay used these days.
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Chemiluminescence.
I feel it is a great pity that the manufacturers of this 
type of HBsAg assay have not put enough effort into 
providing the type of assay required by the Blood 
Transfusion Service. There is great potential for 
quantititation using this assay, and the shorter incubation 
times required would be most useful for the quick release 
of blood.
I
One of the earlier constraints of this assay was the short 
duration of the signal, making it unsuitable for large 
batches of samples. This has now been overcome by the use 
of an enhancer such as firefly luciferin which can increase 
the signal by up to 600 times and also helps to depress the 
signal/noise ratio.
This assay is currently more prone to the problems of 
naturally occurring peroxidases in the serum than other 
enzyme catalysed assays.
Chemiluminescence assays are not subject to the high dose 
"hook" effect until very high (up to 600 ug/ml) levels of 
HBsAg are reached.
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Table to summarise the constraints of RIA. EIA and 
Chemiluminescence.
RIA EIA Chemiluminescence
1.Short half-life 1. Non-specific l.Need to enhance
of reagents.
i
protein binding. signal.
2.Radiation hazard 2. Cross-rectivity 2.Prone to problems
regulations. and natural with naturally
3."Hook" effect at antibodies. occuring peroxid­
high antigen 3. Antibodies to ases .
concentrations. blocking protein
4. Temperature 
variations.
5. Enzyme inhibitor 
may be present.
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Polymerase chain reaction.
Although it is not yet applicable to routine donor 
screening, great success in a research context has been 
achieved using the polymerase chain reaction (PCR) 
(Schochètman et al. 1988) which can allow geometric 
amplification of a target sequence of DNA (Figure 12.). The 
resulting "amplified" DNA can then be detected by 
conventional methods.
In PCR, sequences of DNA or RNA are. amplified in vitro over 
a million times in just a few hours. If an RNA sequence is 
to be amplified, a DNA copy of it must be synthesised by 
using reverse transcriptase before the PCR is begun. The 
principle of PCR is simple. Two oligonucleotide primers 
that flank the DNA segment for amplification are used to 
direct DNA synthesis in opposite and overlapping 
directions. The procedure involves repeated cycles of heat 
dénaturation of the DNA, annealing of the primers to their 
complimentary sequences and extension of the annealed 
primers by DNA polymerase. The primers are oriented so that 
synthesis of the DNA by the polymerase proceeds across the 
region between them. Each cycle of heating, cooling and 
polymerisation doubles the number of copies of the target 
DNA.
In early procedures, an enzyme known as.the Klenow 
fragment, derived from Escherichia coli. was used to build 
the new chains of DNA. This caused problems because the 
high temperature required to separate the two strands of a
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double helix also destroys the ability of the enzyme to 
catalyse polymerisation. This necessitated the addition of 
fresh enzyme at each stage in the reaction. Recently a 
better solution has been described (Science, vol 239, p487) 
in which a polymerase derived from the bacterium Thermus 
aouaticus (Tag), which lives in hot springs and geysers, is 
used. This polymerase survives extended incubation at 
95°C. One addition of enzyme is able to keep working 
throughout ail cycles of DNA amplification. Running the PCR 
at a higher temperature has made the reaction more 
sensitive and more specific resulting in less amplification 
of non-target sequences, as well as giving a higher yield.
The advantages of the polymerase chain reaction lie in its 
high degree of specificity, sensitivity and also its 
simplicity and directness in comparison with previous 
methods of gene isolation and purification. This method 
potentially lends itself to diagnosis of infectious 
diseases because it does not require radioactive detection 
systems. In fact, if sufficient genomic material is 
available, diagnosis can be made by direct visualisation of 
the amplified sequences by staining with ethidium bromide 
after gel electrophoresis. The higher degree of specificity 
afforded by this technique permits the detection of viral 
material even when there is a large excess of host nucleic 
acid. However at this stage the technique is still too 
expensive for routine use.
PCR amplification lends itself well to automation and 
promises a rapid detection method for an enormous number
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and variety of clinical applications although not yet as a 
screening test in the transfusion context. A PCR assay for 
the detection of HBV has been developed and used by 
research workers in apparently healthy seropositive and 
seronegative Chinese individuals ( Pao et al. 1991) who 
have a HBsAg prevalence rate of 25%. But the feelings are 
that at the present time the PCR assay probably belongs in 
the research laboratory until standardised assays are 
available and specificity problems are resolved. This type 
of assay could in,fact be too sensitive in a transfusion 
context, as it would also amplify non-replicating genomic 
material in immune individuals; A more suitable method for 
DNA detection in this context would be the less sensitive 
DNA hybridisation technique. (Dot blotting.).
DNA Hybridisation.
Viral DNA in a specimen is spotted on to a nitrocellulose 
membrane where it is bound and denatured with alkali. It is 
then hybridised with a radioactively labelled viral DNA 
probe and autoradiographed.
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Figure 12.Mechanism of polymerase chain reaction.
ISequence for amplification i double stranded DNA
B
Denature (heat) to separate
strands I
B
Bind the oligonucleotide 
primers that define the ends 
^ of the selected sequences ^
B z^primerj
-(primer)
iSynthesize complementary strands I
B'
B
Repeat the cycle 20-30 times
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In order to prevent thé transmission of HBV to a vulnerable 
population it is necessary to have confidence in the 
sensitivity, specificity and reproducibility of the tests used 
to screen donor blood for the various markers of viral 
infection prior to transfusion. The following section is an 
evaluation of the assays and an attempt to assess the degree
i
of confidence we can place upon them.
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SECTION 3; EXPERIMENTAL EVALUATIONS OF THE ASSAYS EMPLOYED
IN
TRANSFUSION MICROBIOLOGY.
94
3:1 A comparative evaluation of commercially available
HBsAg EIA assays.
During the course of this study the routine method of HBsAg 
screening at NLBTC had to be changed. The BPL RIA assay was 
no longer available to us because of the problems 
associated with the use of radioisotopes and also because 
in order to achieve the required level of sensitivity the 
assay needed to be run overnight. This was considered too 
long to allow for the rapid release of blood for 
transfusion.
It fell to me personally to examine some of the 
commercially available HBsAg diagnostic kits on the market 
with a view to their suitability in the context of blood 
transfusion.
When assessing a diagnostic kit it is necessary to take 
several factors into consideration. It is important to 
achieve a balance between sensitivity, specificity, cost 
and convenience. I firstly canvassed other Blood 
Transfusion Centres to see which assays they were using and 
what sort of results they were obtaining in order to narrow 
down the number of assays evaluated. I then set about 
running a trial batch of 5 coated microplates for each 
assay under trial. Each plate contained both donor samples 
and a range of known standards, specifically the BPL 
standards calibrated to contain 0.1, 0.25, 0.5, 1, 4, 10, 
and 20 nanograms of HBsAg per ml.
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Ideally, several forms of standard would have been 
evaluated at various dilutions and examined for parallelism 
to establish comparable performance with all assays.
However at the time I was restricted to the use of the BPL 
standards, therfore the comparison is perhaps not strictly 
as complete as it might have been, had more standards been 
available to me.
If the assay matched our requirements for sensitivity, i.e. 
to detect 0.2 ng/ml or less, using the BPL reference 
preparations, I then ran a further trial of 1000 donor 
sera to assess specificity. I include the results of these 
trials to give some idea of the range of HBsAg assays that 
are currently available.
Kits Evaluated.
1. Wellcozyme HBsAg amplified ELISA.
2. Biokit Bioelisa HBsAg. (Launch).
3. Fujirebio FRELISA HBs.
4. Amerlite HBsAg chemiluminescence assay
(Amersham International).
5. Abbott Auszyme Monoclonal.
i
6. Behring Enzygnost HBsAg Monoclonal.
7. Mercia Heprofile HBsAg.
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1. Wellcozyme HBsAa amplified ELISA.
Kit Specifications.
The test is a type IV (see note on types of immunoassay) 
"sandwich" amplified ELISA which uses plates coated with a 
mouse monoclonal antibody to HBsAg. The conjugate is 
alkaline phosphatase-labelled mouse monoclonal antibody to 
HBsAg in a serum base. The substrate is NADP, and the 
amplifier contains alcohol dehydrogenase and diaphorase.
Procedure.
The manufacturers offer alternative incubation procedures 
but the 37°C protocol was used for this evaluation as
r
this corresponds to current laboratory practice in testing 
for other infectious agents, and is suitable for testing 
plasma as well as serum. (Higher incubation temperatures 
may not be used for plasma samples.) The incubation was 
carried out in an air incubator on a heating block inside a 
wet box.
There are three incubation periods and one washing stage. 
Total assay time is approximately two and a half hours 
including sampling, washing and reading.
Controls per plate are 4 negatives and 2 positives.
i ‘ •
Reading is performed at 492 nm.
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Calculation of the cut-off is performed by taking the mean 
of the negative controls and adding 0.1.
Observations.
The coefficient of correlation obtained for a standard 
curve employing the BPL positive standards was 0.9866.
The assay was sensitive to 0.2 ng/ml but the cut-off was 
set rather high and there was a noticeable difference 
between the negatives and the 0.1 ng/ml standards. 
Extremely low levels of both.AD and AY subtypes could be 
detected ( i.e. at a dilution of 1 in 300,000 ).
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2. Biokit Bioelisa HBsAo. (Marketed by Launch Diagnostics^ 
Kit specifications.
The assay is a type IV "sandwich" polyclonal ELISA using 
plates coated with guinea-pig anti-HBs, and goat anti-HBs 
conjugated with peroxidase. The substrate is hydrogen 
peroxide and the chromogen is TMB (tetramethylbenzidine).
Procedure.
Incubation can be either overnight at room temperature or 
at 40°C in either a waterbath or an air incubator.
There are three incubation periods and two washes. Total 
assay time is just over, two and a half hours including 
sampling, washing and reading.
Controls per plate are 2 blanks, 5 negatives and 1 
positive.
Reading is performed at dual wavelengths of 450 nm with a 
reference filter of 620 nm.
Calculation of the cut-off is performed by taking the mean 
of the negatives and adding 0.04.
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Observations.
The coefficient of correlation obtained for a standard 
curve employing the BPL positive standards was 0.9937.
Difficulties were encountered when attempting to calibrate 
the plate reader against wells as directed by the 
manufacturer. Valid results were obtained if the reader was 
calibrated against air. The manufacturer confirmed that 
this v^ as a valid procedure.
The lowest level of HBsAg to be 100% detectable for this 
assay was 0.25 ng/ml.
Figure 13.
Plate
number
mean
cut-off
number of 
reactives
"grey zone" 
reactives
percentage 
reactive rate
1 0.159 2 0 2.3
2 0.154 0 0 0.0
3 0.160 1 1 1.2
4 0.134 0 5 0.0
5 0.128 0 1 1.2
6 0.141 0 . 1 ' 0.0
7 0.136 1 2 1.2
8 0.113 1 4 1.2
Total 0.141 5 14 0.7
Batch number J-4890
"grey zone" = cut-off +/- 10%
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A further evaluation of the test using six plates of donor 
sera resulted in two false positive reactions involving 
contamination of the well at substrate addition stage.
Trials of a short incubation version of this assay were 
done using the normal freeze-dried conjugate and the new 
liquid conjugate. Initially, sensitivity was reduced but on 
shaking the plates in a shaker-incubator, sensitivity was 
restored to a detection limit of 0.25 ng/ml. using the 
freeze-dried conjugate. The use of the new liquid conjugate 
improved the specificity of the test leading to a reduction 
in false-positivity.
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3. FRELISA HBs (Fuiirebio).
Kit Specifications.
The assay is a one-step "sandwich" method ELISA, using 
plates coated with a mouse monoclonal anti-HBs. The 
conjugate contains another mouse monoclonal anti-HBs and 
horseradish peroxidase. The chromogen is OPD. Therefore 
incubation with the substrate has to be performed in the 
dark.
Procedure.
The sample and conjugate are initially incubated for one 
and a half hours in an air incubator at 37°C. The 
substrate is added and the second incubation is for 30 
mins. at room temperature.
Total assay time including sampling and reading is two and 
a half hours.
Controls per plate are 3 negatives and 2 positives.
i
Calculation of the cut-off is performed by taking the mean 
of the negative controls and adding 0.5.
Reading is by dual wavelength at 414/492 nm.
Observations.
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The coefficient of corrélation for a standard curve 
employing the BPL positive standards was 0.9905.
Standards less than 0.5 ng/ml were negative by this assay.
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4.Amerlite HBsAq . Amersham International.
Kit Specifications.
The assay is a type IV labelled antibody sandwich assay 
using a chemiluminescent enzyme as a label. Microplates 
coated with mouse monoclonal anti-HBs comprise the solid 
phase. The conjugate is a mouse monoclonal anti-HBs of a 
different specificity conjugated with horseradish 
peroxidase. The substrate contains luminol and a peracid 
salt.
Procedure.
The signal reagent, signal reagent buffer and the wash 
buffer are common to all Amersham assays and are not 
provided with the kit.
The wells are packed in strips and the plate has to be 
manually assembled before use. Assembly of a sufficiently 
flat plate surface suitable to pass easily through the 
washer and analyser is difficult to achieve as some of the 
wells are prone to protrude from the surface.
Initial incubation is one hour in the Amersham shaking 
incubator at 37°C. The plate is washed and the substrate 
containing the signal regent is added and the plate can be 
read 2-20 mins after addition.
104
The plate is read in the Amerlite Analyser which provides a 
printout of all results in a choice of formats.
Total assay time including sampling, washing and reading is 
approximately one and a half hours.
Controls per plate are 3 negatives and 3 positives. However 
they are not in the conventional positions and the software 
is geared to these non-standard control positions at 
present.
Calculation of cut-off is performed by the analyser which 
normalises the signal. All readings greater than 1 are 
flagged as reactive.
Observations.
Sensitivity of this assay differs according to the subtype 
but 0.5 ng/ml must be considered as the lower limit of 
detection. Using the manufacturer's cut-off criteria.
This assay is fast but not as sensitive as others tested.
Larger scale clinical trials of this assay had been
i
previously performed at NLBTC and extensive evaluation 
results are available.
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5.Abbott Auszvme Monoclonal.
Kit specifications.
The assay is an EIA using a coated bead as the solid phase. 
The bead is coated with a mouse monoclonal anti-HBs. The 
conjugate is mouse monoclonal anti-HBs peroxidase (HRPO). 
The substrate is OPD.
The assay uses the Abbott Commander flexible pipetting 
centre and parallel processing centre. The beads are 
incubated in the Abbott plastic trays and the system is not 
compatible with the microtitre system. Abbott provide an 
air incubator and a "dynamic" or shaking incubator is 
shortly becoming available.
Observations.
The initial incubation of sample and conjugate is 75 mins. 
at 40°C .(There are three different protocols including 
an overnight and a three hour incubation). Incubation with 
the substrate takes 30 mins at room temperature under cover 
to exclude light.
Dispensing of reagents is performed by the processor and 
all reading is done inside the processor.
The total assay time excluding pipetting was just over two 
hours. However the use of an automated sampler would 
increase the processing time accordingly, but would add the
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benefits of barcoded trays and positive sample 
identification.
Controls per run are two positives and three negatives but 
this one set of controls can be used for up to ten trays in
a.batch.
Reading is performed in the processor at 492 nm within two 
hours of the addition of IN sulphuric acid, again performed 
by the processor.
Calculation of the cut-off is performed by taking the mean 
of the negatives and adding 0.025.
Observations.
The correlation coefficient obtained for the BPL standards 
was 0.9976.
The assay was able to detect the O.lng/ml standard in 11 
out of 12 replicates.
A 1000 test trial-run performed in the lab resulted in only 
1 false positive result.
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6. Behring Enzyanost Monoclonal.
Kit specifications.
The test is a one-step EIA using plates coated with sheep 
anti-HBsAg. The conjugate is monoclonal anti-HBs conjugated 
with peroxidase and preserved with phenol max.lg/1. The 
substrate is TMB.
Procedure.
Initial incubation is for 90 minutes at 37°C in either . 
air or water but water is preferred. There is only one 
washing stage and the second incubation is in the dark at. 
room temperature.
Total assay time including sampling and washing is 
approximately two and a half hours.
Contrbls per plate are 4 negatives and 2 positives.
Reading is at 450 nm.
Calculation of the cut-off is performed by taking the mean 
of the negative controls and adding 0.05.
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Observations.
The coefficient of correlation for a standard curve using 
the BPL positive standards was 0.9839.
The limit of detection for this assay was 0.25 ng/ml. 
Behring have available a fully automated processing system, 
and full hardware and software back-up is also available.
109
7. Mercia Heprofile HBsAa.
Kit specifications.
The test is a type IV "sandwich" ELISA which uses plates 
coated with mouse anti-HBs. The conjugate contains 
peroxidase and chimpanzee anti-HBs. The substrate is 
hydrogen peroxide and the chromogen is TMB.
Observations.
Incubation times vary with accompanying variations in 
sensitivity. There is a 90 min. incubation, a two and a 
half hour incubation and an overnight incubation. The 90 
min incubation is sensitive only to 0.5 ng/ml. The two and 
a half hour incubation is claimed to be sensitive to only
0.25 ng/ml, but in the trial run it was possible to detect 
four out of eight replicates of 0.1 ng/ml. The overnight 
incubation is said to detect 0.125 ng/ml but was not 
attempted in this trial. Incubation may be carried out in 
air or in a waterbath at 37°C or at room temperature 
overnight.
There are three incubation periods and two wash steps. The 
shortest possible assay time would be one and a half hours 
including sampling and washing.
Controls per plate are 3 negatives and 2 positives.
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Reading is at 450 run.
Calculation of the cut-off is performed by taking the mean 
of the negative controls and adding 0.05.
Observations.
The coefficient of correlation obtained for the BPL 
positive standards was 0.9886.
In our hands, the sensitivity was better than that 
predicted by the manufacturers, detecting four out of eight 
replicates of the 0.1 ng.ml standard when using the two and 
a half hour protocol.
Ill
Figure 14.
Tables of Reproducibility.
1.
Wellcozyme HBsAa.
ng/ml 1 0.1 1 
1 1
0.25 1 0.5 1 1 1 4 10
n 1 11 1 
1 1
11 1 8 1 10 1 
1 1 1
18 8
mean OD 1 0.235 1 
1 1
0.309 1 0.394 1 0.5621 
1 1 1
1.489 2.765
SD 1 0.013 1 0.019 1 0.137 1 0.0431 
1 1 1
0.079 0.082
CV 1 5.53 1 6.15 1 5.398 1 7.65 1 5.3 2.99
Cut-off
2.
= 0.283
Biokit Bioelisa HBsAa rLaunch1.
ng/ml 0.1 1 0.25 
1
0.5 1 1 1 4 1 10 
1 1
n 16. 1 16
1
8 1 
1
8 1 8 1 10 
1 1
mean Ob 0.072 1 0.1196 0.179 1
1
0.3131 1.0151 1.997
sb 0.00391 0.005 0.0085|
1
0.0121 0.0281 0.036
CV 5.44 1 4.28 
1
4.73 1 
1
3.9771 2.78 | 1.79
Cut-off = 0.0928
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Tables of reproducibility cont.
3. Abbott Auszvme.
1 ng/ml 
1
1 0.1
I
1 0.25 
1
1 1 
1
4
1 n 
1
1 12 1 12 
1
1 10
1
. 12
1 mean OD 1 0.04
4
1 0.09 
1
1 0.28 
1
0.86
1 SD 1 3.57 
1
1 6.48 1 0.013
1
0.06
1 CV 
1
1 8.94 1 6.95 1 4.55
■ I
7.01
Cut-off = 0.032
. 1-
. ■
4. Behrina Enzvanost.
1 ng/ml 
1
1 0.1 1 0.25 
1
1 0.5 1 • 1 1 
_  1
.4 1
1 ^ 
1
1 6
1
1 6 
1
1 6 1 6 1
1
6 1 
1
1 Mean OD 1 0.117 1 0.16 1 0.2321 
1 1
0.36 1 1.01 1 
1
1 SD 
1
1 0.012 
1
1 0.014 1 0.117| 
1 1
0.02 1 0.05 1
1 CV 1 10.08
.1 . .
1 8.48
.....1........................
1 5.07 1 
1 1
6.16 1 
1
5,17 1 
1
Cut-off = 0.148
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Tables of Reproducibility cont.
5.Mercia Heorofile
1 ng/ml 
1
0.1 0.25 1 0.5 1
1 1
1 4 1 
1
1
1 ^ 8 8
1 1 
1 8 1 8
1
8 1
1
1 mean OD 0.202 0.28
1 1 
1 0.46 1 0.82
1
2.497|
1 SD 0.011 0.017
1 1 
1 0.0361 0.03
1
0.08 1
1
1 CV 5.388 5.97
1 1 
1 8.02 1 3.86
1
3.2 1
Cut-off = 0.201
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Summary of methods of calculation of cut-off in HBsAq 
Assayë.
I include this brief summary to illustrate that whatever 
careful trials and evaluations are performed in the 
laboratory, the ultimate decision of a positive or negative 
result is set by the manufacturer by the use of a "factor" 
based on calculations performed in their own Q.C. 
department! It would be possible also to set the "cut-off" 
from the mean of the negative samples on the plate plus two 
standard deviations, thus reflecting the true performance 
of the assay. Care must be taken to exclude outliers. Some 
sera, through non-specific binding (see page 86) give 
falsely high readings leading to an artificially high 
cut-off and hence reducing sensitivity. Equally, falsely 
low readings would lead to an artificially low cut-off and 
a resulting loss of specificity. This method has been 
considered as an option at NLBTC but not implemented 
because, due to product liability constraints, we are 
required to adhere strictly to the manufacturer's criteria 
for the establishment of the cut-off.
1. Wellcozyme.
Take the mean of the negative controls and add 0.1.
i
2. Biokit Bioelisa.
Take the mean of the negative controls and add 0.04.
3. Fuiirebio FRELISA.
Take the mean of the negative controls and add 0.5.
4. Amerlite HBsAa.
Calculation of the cut-off is performed by the Amersham 
Analyser, which normalises the signal and flags all 
readings greater than 1.
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5. Abbott Auszyme.
Take the mean of the negatives and add 0.025.
6. Behring Enzyanost.
Take the mean of the negative controls and add 0.05.
7. Mercia Heprofile HBsAa.
Take the mean of the negative controls and add 0.05.
I feel that we have chosen the most appropriate assay 
method for our requirements because, not only does the 
assay meet national requirements for sensitivity, but 
also, most of the reactives we see are genuine 
neutralisable positives. Our initial reactive rate 
currently stands at 0.08% which by any standards is a very 
clean assay, but particularly so with an EIA assay (see 
page 86). It is now very rare to see a repeatable 
false-positive reaction by this assay. However, this cannot 
be said of all EIA assays evaluated (see previous data ). 
Non-repeatable reactives are usually due to technical 
errors.
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Figure 14 fat.
Typical distribution of negatives plus 11 positives on 163 assays 
performed using the Biokit Bioelisa HBsAg assay. The results are 
normalised to the cut-off hence anything greater than 1 is 
positive.
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Figure 14 fbt.
Distribution of the means of the negative samples on the same 163 
assays most fall within two standard deviations of the mean, 5 are 
outside this range reflecting variation in incubation conditions as 
the plates are batched before incubation.
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Figure 14 fci.
Typical distribution profile of negative samples using the SPRIA 
for HBsAg. My thanks to Dr. David Howell for this illustration.
3:2 Evaluation of assays used in this study.
In order to affirm the validity of the data collected, it 
was necessary to perform an evaluation of the 
reproducibility and precision of the main assays used in 
the provision of the data over the years. This was in order 
to show that where changes in titre or where 
séroconversions had occurred, we were looking at 
significant differences and not just normal or experimental 
variations.
Evaluation of precision and reproducibility of RPHA assay.
i
Aim: To perform a series of end-point titrations on a 
sample of known HBsAg titre (1:64 by 1% Hepatest) and to 
observe the reproducibility of the test under standard 
laboratory procedures.
Method: Two operators worked in parallel for this 
evaluation. The 1:64 standard was titrated 10 times in 
parallel by 1% Hepatest (Wellcome Diagnostics) by both 
operators on one day using a single batch of test reagents. 
The next day, both operators repeated the same procedure 
again using the same batch of reagents.
After an interval of one week, the procedure was again 
repeated, this time using a different batch of reagents.
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Titration. 0.025 ml of kit buffer was added to the wells of 
two U-well microtitre plates per operator. The test and 
control cells were reconstituted in 0.025 ml of kit buffer 
as per manufacturer's instructions. 0.025 ml of the 
standard was serially diluted in the wells of the 
microtitre plates to give dilutions of 1:2, 1:4, 1:8 etc. 
until the final well gave a dilution of 1:256. This was 
repeated in two rows of wells for each sample tested to 
give a row of test dilutions and a row of control 
dilutions. This test was repeated using the same standard, 
five times in each plate. The kit positive control serum 
was then similarly diluted in the last two rows of each 
plate, and with a 0.025 ml dropper, 0.025 ml of the test 
and control cells were added to alternate rows of the 
plates. The plates were allowed to settle undisturbed on 
the bench for 30 minutes until the agglutination patterns 
were yisible in the bottoms of the wells.
Interpretation of results.
A positive reaction was deemed to be one in which a smooth 
carpet of cells could be seen at the bottom. A negative 
well was one in which a tight button of cells could be seen 
at the bottom. Reference was made to the positive control 
titration to help determine the reaction pattern that 
would be taken as the " cut-off ".
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Results ; The results of these test runs were compared and 
analysed (see figures 15-18.)
Figure 18; Summary of Haemaaalutination Evaluation Result
Run No. Operator 1
1 .1 Frequency Titre C.V. 1 Frequency titre 1 C.V .
1 1 1 8 64 1 8 64
1 1 2 32 6.8 1 2 32 1 6.8
1 2 1 8 64 1 7 64 1
1 1 2 32 6.8 1 3 32 1 8.7
1 3 1 9 64 1 8 64 1
1 1 1 32 1 1 32
5.1 1 1 128 1 7.4
Batches used were K15861 for runs 1&2, and K634310 for run 3.
Operator 2
Comment. Coefficients of variation are as in figure 18. The 
differences in them are very small: i.e. between 5.1 and 
8.7. but this is not directly comparable with those for the 
RIA assay since the HA is logarithmic.
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Evaluation of Precision and Reproducibility of SPRIA Assay.
Aim : To perform a series of replicate RIA tests on a 
sample of known HBsAg content (Ing/ml B.P.L. Elstree) and 
to observe the spread of counts per minute under standard 
laboratory procedures.
Method : A sufficient number of wells were coated under 
normal laboratory conditions with horse anti-HBs l/lOOO 
(B.P.L. Elstree) for 3 days at room temperature, and then 
with bovine serum albumin for 2 hours at room temperature.
0.1 ml of the Ing/ml standard was inoculated into each test 
well.
The plates were then incubated for 2 hours in a waterbath
at 45°C. They were then washed x 5 in deionised water,
125and 0.1 ml of I goat anti-Hbs label was added to each 
test well. The plates were re-incubated in the waterbath 
for a further 2 hours before being rewashed x 5 in 
deionised water. The wells were then separated and counted 
in a 16-channel gamma counter for 60 seconds.
The above procedure was repeated on three separate runs by 
the same operator (the author), at intervals of one week, 
using two replicate plates of 96 wells, to give a good 
range of test values.
Results ;
Statistical analysis was performed on the data obtained.
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Figure 19: Diagrammatic representation of C.V. ranges on each day.
C.V. 9 10 11 12 13 14 15 16 17
(Percent) J_^ _____________
Range.
Day Is J_______ 1
Pay 2: 
Day 3:
Comment;
Within a run, coefficients of variation vary by 2% or less 
(i.e. little variation). However, on different days the C.V.s 
can vary by as much as 8%. In the context of biological assay 
variation, however, 8% is a very favourable value considering 
that titrations such as RPHA are considered to have an 
accuracy of +/- 1 well (i.e. +/- 100% variation) 16— 32— 64. 
It was therefore concluded that a significant difference in 
RPHA titre would be a fall ( or rise) in titre by three wells 
or more. Variation of one, or even two wells could be 
construed as experimental variation. RIA, or equivalent 
immunoassay, would therefore be the assay of choice for the 
examination of significant falls in HBsAg quantitation as RPHA 
titres are less accurate.
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Calculation of reproducibility of Bioelisa HBsAa.
All data in this study refers to results obtained by SPRIA and 
HA. However, during the progression of this study NLBTC 
changed from these two assays to an ELISA as their definitive 
test (March 1991). For completeness some data on this test has 
been included, since any further data in future studies will 
probably be obtained by this or a similar method.
In order to assess the reproducibility of this assay, it was 
used to assay several replicates of the BPL nanogram standards 
and the coefficients of variation were calculated.
Results.
Figure 28; reproducibility of Bioelisa HBsAcr.
ng/ml 0.1 . 1 0.25 1 0.5 1 
1 1
1 1 
1
4 10
n 16 1 
1
16 1 8 1 
1 1
8 1 
1
8 10
mean OD 0.072 1 0.1196 1 0.179 1
1 _ i
0.313 1
1
1.015 1.997
SD 0.0039 1 0.005 1 0.0085 1 
1 1
0.012 1 
1
0.028 0.036
CV 5.44 1
1
4.28 1 4.73 1
1 i
3.977 1 
1
2.78 1.79
Cut-off = 0.0928
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Observations.
The coefficients of variation show that in our hands this 
assay is certainly acceptable from the point of view of 
reproducibility. In this instance it exhibits a better 
coefficient of variation than either the RIA or the 
haemagglutination assay (see earlier data).
i
Many years of screening for HBsAg in donated blood at NLBTC 
has yielded a wealth of data. In section 4 I have attempted 
to summarise some of our data and compare it with some of 
the information provided by other workers in the field.
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SECTION 4; RESULTS AND ANALYSIS OF DATA.
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4 ;1 Resource Material.
For the past eighteen years the North London Blood 
Transfusion Centre has maintained a library of samples 
collected from volunteer blood donors who have been found 
positive for hepatitis B surface antigen (HBsAg). By means 
of clinical, biochemical and serological analysis, these 
donors have been differentiated into thosd suffering from 
either an acute or a chronic HBV infection.
During the course of their infection, regular follow-up 
samples of HBsAg positive donors are obtained and examined 
for the relevant HBV markers in order to determine the 
nature and course of the infection. We are particularly 
interested in the rates of loss of. surface antigen in the 
long term. This information helps us in the job of 
counselling donors and gives the donors confidence that 
their condition is being regularly monitored. It also 
reduces the chances of donors returning to donate on the 
normal donor panel. We are also able to discuss with them 
the relevance of the carrier state in terms of its effect 
on their sexual relationships, their offspring and their 
medical treatment, by monitoring levels of infectivity 
(HBeAg/Ab status). We also couple surface antigen testing 
with liver function tests and/or AFP as an index of 
c arc inogenic ity.
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The results of all tests are collated on â computer 
database. This large reservoir of data provides us with 
material for long-term research in terms of the longevity 
of carriage of HBsAg, duration of infectivity and prognosis 
with regard to clearance of viral material and the 
likelihood of developing further complications such as 
primary hepatocellular carcinoma. By defining the 
characteristics of HBsAg positivity and by studying this in 
the context of the donor population of the centre and also 
nationally, it should be possible to be able to outline a 
spectrum of HBsAg reactivity and in particular to assess 
annually the range of rates of decline of HBsAg levels in 
different carriers. Therefore in future studies, if a group 
of carriers is identified as showing a rapid decline in 
HBsAg I will be able to examine any correlations between 
various parameters such as age, sex, ethnic origin, subtype 
or HBe status.
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4:2 Definition of population.
At NLBTC the records of all HBsAg positive donors 
followed-up are held on a computer database on a Data 
General Super MV 10000 using an in-house software package. 
The Antigen Donor Information System (ADIS) is designed to 
allow the storage, alteration and retrieval of information 
relating to hepatitis B surface antigen positive blood 
donors. An example of the stored information can be seen at 
figur^ 29. The information is divided into three different 
types :
Header information is information such as the donor's name, 
sex, date of birth, country of birth etc., i.e. items that 
occur only once for each donor, except that a donor may 
have more than one name.
Results information consists of the results of 
microbiological tests on samples from various bleed numbers 
and dates. Where a donor has only one header record he/she 
may have any number of results records.
Notes are simply textual records similar to medical notes.
There is also a data search facility written in to the 
software but this is very limited at present.
The regular updating of the donor records is done on a 
monthly basis and is the responsibility of the author.
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4;3 Analysis of donor population at NLBTC.
Definition of the background characteristics 
of the HBsAg positive population at the NLBTC.
As of 6th September 1988 the HBsAg-positive donor 
population on record at NLBTC was analysed as follows :
(i) The total number of HBsAg-positive donor records from 
1971 was approximately 900 (i.e. 53 HBsAg positive donors
per year overall).
(ii) From May 1974 detailed records have been kept and 
more detailed analysis will be based on these donors.
a) Surface antigen positive rate at NLBTC 1980-1990 (see 
figure 30.)
h
Year Total number. HBsAg pos rate(%)
1980 50 0.029
1981 53 0.029
1982 48 0.027
1983 41 0.022
1984 . 40 0.021
1985 25 0.013
1986 27 0.013
1987 30 0.015
1988 34 0.017
1989 40 0.020
1990 23 0.012
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The HBsAg positive rate shown for 1980 and 1981 are 
representative of the rates for previous years.
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Figure 30,
Summary of the HBsAg positive rate at NLBTC 1980-1990.
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Figure 31.
HBsAg acute infection rate at NLBTC 1980-1990.
b) Acute infection rate as a percentage of all HBsAg positive donors 
at NLBTC per year. (See figure 31.)
Year Acute infections as a percentage 
of all HBsAg positive donors.
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
10%
13.45%
12.22%
15%
20%
8.46%
7.69%
0.00%
3%
0.00%
8%
c) HBsAg acute infection rate at NLBTC 1980-1990. (See figure 
32)
Year Total No Acute infection rate(% ^
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
0.0029
0.0039
0.0033
0.0033
0.0042
0.0011
0.0010
0.0000
0.00051
0.0000
0.0015
Figure 32 (a) shows the laboratory reports of acute infétions in the 
U.K. From, the Communicable Disease reports from the Public Health
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Laboratory Service. The sharp drop in infections seen at NLBTC was not 
seen nationally until 1988. This presumably reflects public awareness 
of HIV infection and the need to modify behaviour. The previously high
j
levels around 1984 and 1985 were attributable to a large increase in 
intravenous drug abuse and a slight increase in homosexual 
promiscuity.
Laboratory reports of acute HBV in the U.K. 1980-1990.
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1007
1197
1237
1274
1*937
1771
1313
775
636
588
564
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HBsAg acute infection rate as a percentage of the total donor 
population at NLBTC 1980-1990.
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Raw figures for population studied.
The population for close analysis was limited to those donors 
who fulfilled the following conditions:
1. There should be more than one donation or sample on 
record.
2. These donations/samples should be at least 3 months 
apart.
The resulting population was then analysed by a search of the
i
data files:-
No of donors with selected criteria = 332
No of acute infections = 47
No of carriers =286
No of carriers HBeAg pos at detection =35
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Table 3. Acute Infections.
Total number 47
Males 42 (89.4%)
Females. 5 (10.6%)
Unknown gender 0 (0.0%)
New donors 14 (29.8%)
Old donors 27 (57.4%)
Previous donations at other centres 5 (10.6%)
Unknown donation history 1 (2.2%)
Born outside U.K. 7 (14.8%)
Born in U.K. 32 (68.1%)
Unknown country of birth 8 (17%)
Elevated LFT (>30) 19 (40.4%)
Table 4.Carriers.
Total number 286
>4 donations 151 (52.98%)
Males 202 (70.8%)
Females 77 (27%) ,
Unknown gender 7 (2.5%)
New donors 215 (75.4%)
Old donors 38 (13.3%)
Previous donations at other centres 26 (9.1%)
Unknown donation history 7 (2.5%)
Born outside U.K. 119 (41.8%)
Elevated LFT (>30) 128 (44.9%)
NB we do not have any data available on the risk status of the 
partners of our donors.
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4 ; 4 Changes in HBe Status.
Changes in the HBe status were examined in detail. 35 (12.28%) 
of the 286 carriers studied were HBeAg positive at the time of 
pick-up, 27 (77.14%) of these 35 maintained their HBeAg 
positivity throughout their period of follow up. 8 (22.9%) of 
the 35 initially HBeAg positive went on to lose their HBe 
antigen and developed anti-HBe during the time we were able to 
follow them up.
At no time in the study did any carrier revert from anti-HBe 
to HBeAg.
It is also worth mentioning here that one of our donors who 
seroconverted from HBeAg to anti-HBe subsequently was found to 
have been undergoing Interferon therapy. It is interesting to 
note that he had shown changes in his liver function tests 
prior to seroconversion. The question remains, was his e 
seroconversion actually brought about by the Interferon 
therapy or just as the natural result of long-term carriage?
It is noteworthy that we had documented his HBeAg status for 
13 years prior to his e seroconversion. .
Of the 286 carriers studied, 12 in all (4.2%), showed a change 
in HBe status; of these 12, 8 went from HBeAg to anti-HBe, 3 
went from e neg, (neither detectable) to anti-HBe, and 1 went 
from anti-HBe to e neg during their follow-up period . The 
range of follow-up time for this group of 12 was 0.819 to 13.6 
years and the mean follow-up time was 5.73 years. Of the 12
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with HBe status changes 5 were of the ay subtype, whilst 6
were of the ad subtype. 1 was not subtyped. Also of these 12,
i
5 were born outside the U.K., 6 were born in the U.K. and 1 
was of unknown country of origin. 8 of the 12 were males, 4
were female. 5 of them had stable titres whilst 7 showed a
fall in titre (3 of them by a significant amount i.e. by a 
factor of three twofold dilutions or more.)
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Figure 33
Summary table of donors showing a change in HBe status.
HBe Donor 1 Country |Carrier 1 Years of subtype no.of donations| sex
Status No. I of Orig.I Status 1 follow UD on record. |
Ag>Ab 178 1 UK 1 D 1 11.814 ad 19 1 F *
Ag>Ab 324 1 0 1 D* 1 10.033 ad . 8 1 M
Ag>Ab 357 1 UK 1 ,D* 1 8.008 ay 19 1 M
Ag>Ab 396 1 0 1 D* 1 0.942 : ' ad ’ ■ ' 3 1 F
Ag>Ab 418 1 UK 1 S 1 7.211 ad 8 1 F
Ag>Ab 531 1 UK 1 D 1 3.030 ad 5 1 M
Ag>Ab 534 1 u 1 D 1 13.329 ay 32 1 M
Ag>Ab 869 1 UK 1 S 1 1.016 U 2 1 M
N>Ab 131 I, 0 1 S 1 0.819 ay 3 1 M
N>Ab 243 1 UK 1 S 1 13.6 , ad 12 1 M
N>Ab 677 1 0 1 S 1 6.334 ay 8 1 M
Ab>N 159 1 0 1 D 1 2.570 ay 3 1 F
key: D = HBsAg titre falling by less than 3 dilutions.
D* =HBsAg titre falling by greater than or equal to
3 dilutions.
S = HBsAg titre stable. M =: male . F = female.
U = unknown gender.
0 = born outside U.K.
Ag= HBeAg 
Ab= anti-HBe
N= neither HBeAg or Ab detectable.
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D o n o r M 2 6 5
N u m b e r M 1 3 5
(11=35) M 73
0  M 5 0 0
M 534
M 3 7 1
M 21
F 178
M 456
0  M 375
0  M 420
U 479
M 516
0  M 324
H B e F 418
s t a t u s M 357
b y M 5 3 1
R I A M 87
M 8 8 0
0  M 9 03
M 43
0  M 321
M 257
M ■ 353
0  M 930
0  F 396
M 830
0  M 255
M  . 261
M 561
M 826
. F 869
0  F 952
0  M 601
0  M 874
each bar repreneiits hlie 
total period oT Follow up 
within the study period 
M= male 
F= female 
U= unknown gender 
0= b o m  outside U.K.
4-- 1
T i m e  of 
p i c k  u p
8 9 10
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Ke y : 4=fBeAq; —  I=Neoafrlve; anti-'33e.
HBe status by RIA throughout period of follow-up for those donors 
HBeAg positive at time of detection.
stability of HBeAa in population studied.
Out of a total of 286 carriers of HBsAg studied, 35 
(12.28%) were positive for HBeAg at the time of detection. 
29 were male, 5 were female, and one was of unknown gender. 
27 of these 35 (77.1%) maintained their positivity for 
HBeAg throughout their period of follow-up. The mean period 
of follow-up for this group of 27 was 3,5 years. The range 
of follow-up time was 0.31 to 13.3 years. Of these 27 
donors, 19 (70.4%) were subtyped and 17 (89.5%) of these 
subtyped donors were of the ad subtype, however ^  is the
i
prominent subtype in our donor population (59%) see 
Vox.Sang. 32:4-9 (1977). Of the remaining 2, one was ay and 
the other was ady. Also in this group of 27 donors, 17 
(89.5%) showed an initial rise in LFT values, 4 (14.8%) 
showed a subsequent rise in LFTs and 6 (22.2%) remained 
within normal bounds for LFTs.
Titres of HBsAg for this group of 27 HBeAg positive donors 
ranged from 1 in 320 to 1 in 12,800. 17 (62.96%) of the 27 
maintained a stable titre whilst 10 (37%) showed a drop in 
titre, 4 of whom showed a significant (3 wells or more) 
fall in titre during their period of follow-up.
Also in this group of 27 HBeAg positive donors 13 (48%) 
were born in the U.K. whilst 10 (37%) were born outside the 
U.K. The country of birth of 4 was unknown.
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Figure 35. Table to summarise overall HBe status of eight donors who 
exhibited HBe seroconversion during follow-up.
Donor No Duration of Markers
HBeAq Negative
178 |May
1
71- Oct 76 
5.42 vrs. 1
|Oct
1
76- Feb 
6.33yrs.
83 1 11.8
324 1 Jul 78— Mar 82 
3.83vrs.
|Mar
1
82- Aug 87 
5.42yrs.
|Aug
1
87- May 
0.78yrs.
88 1 10.03
357 |Oct79- Dec 83 1 Dec 83- Aug 85 |Aug 85- Feb 88| 8.01
1 3.16yrs. 1 1.66yrs 1 2.5yrs 1
396 [Mar 80- Mar81 
lyr.
|Mar
1
81- May 81 
0.16yrs
1
1
1
1
0.94
418 |Oct
1
77- Feb 81 
3.33yrs
1
1
|Feb
1
81- Apr 
3.16yrs
84 1
t
7.2
531 |Dec
1
78— Aug 81 
2.66vrs.
1 |Aug
1
81- Mar 
0.58yrs
82 1 
1
3.03
534 1 Jan 
1
75- Apr 83 
8.25yrs.
|Apr
1
83- Dec 87 
4.66yrs.
1 Dec 
1
87- Jul 
0.58yrs.
88|
1
13.329
869 |Aug
1
86- Mar 87 
0.58yrs.
1
1
|Mar
1
87- Dec 
0.7 5yrs
87 1 
1
1.016
total years
anti-HBe
(Dates accurate to the nearest month only.)
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Correlation between raised LFT values and HBeAa 
seropositivity.
Of the 35 donors who were HBeAg positive at the time of 
detection, 24 (69%)exhibited elevated LFT values during the 
period of follow-up reflecting the association of HBeAg 
positivity and the presence of relatively large quantities 
of infectious virus. However seroconversion from HBeAg 
offers a better prognostic index since, out of the 8 donors 
who seroconverted from HBeAg during their time of 
follow-up> 5 were observed to reach a peak of ALT value 
prior to the point of seroconversion and in those who were 
monitored beyond the point of seroconversion the ALT levels 
eventually fell to within normal levels ( see table of 
normal values).
i
Figure 37. Table to show normal liver function test ranges.
total protein: 62-82 g/1 
albumin: 36-52 g/1
AST: male : 4-45 iu/1
female: 4-30 iu/1
ALT: male : 4-52 iu/1
female: 4-29 iu/1
GGT male : 5-80 iu/1
female: 5-46 iu/1
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■Association between a rise in serum liver enzyme 
concentrations and the presence of HBeAa.
i
It has been suggested that the presence of HBeAg is closely 
associated with a slight rise in serum liver enzyme 
concentrations, a high HBsAg titre, and male sex. (Barbara, 
Mijovic et al. 1978) Examination of the population in this 
study would seem to corroborate this (see tables).
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Figure 37.
Table of relationship between HBe and LFT.
HBe Status : Ab Ab* Ao Ag* N N* U all
LFT levels 
No 107 0 6 1 10 1 43 168
No* 19 1 4 1 1 0 0 2fe
R 25 0 16 5 5 1 10 62
R* 8 1 1 1 0 0 2 13
U 5 0 0 0 3 0 8 16
all 164 2 27 8 19 2 63 285
Key: Ab= anti-HBe positive.
Ab*= initially anti-Hbe positive but result changed on subsequent 
samples.
Ag= HBeAg positive.
Ag*=HBeÀg positive at time of detection but result changed on 
subsequent samples.
N= neither HBeAg nor anti-HBe present.
N*= initially neither marker detected, but. result changed on 
subsequent samples.
U= result unknown.
No=no rise in LFT values.
No*=No initial rise in LFT values but a rise for subsequent 
samples.
R= rise in LFT values.
R*= initial rise observed in LFT values but resumed normal levels 
,for subsequent samples.
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4:5 Changes in titre of HBsAg.
Out of a total population of 286 carriers of HBsAg, 156 
(54.7%) maintained a stable titre of HBsAg. 52 (18.2%) 
showed a significant fall in titre i.e. by three or more 
dilutions during the period of follow-up. 78 (27.4%) showed 
a fall of less than three dilutions during the period of 
follow-up.
Figure 39. Ranges of follow-up times in years for all carriers in
study.
Titres of HBsAg. 1 minimum | maximum | mean
Stable titres
1 1 
1 0.258 1
1
16.762 1 3.542
Falling <3 wells 1 0.277 1 13.710 1 4.946
Falling >=3 wells 1 0.942 1 16.997 1 8.465
Total 1 0.258 1 16.997 1 4.820
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4:6 Some typical donor HBsAa titre profiles with time.
On the following five pages some typical donor profiles are 
represented graphically.
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Discussion.
In this study I have attempted to illustrate the role of 
the hepatitis B virus and its associated markers in the 
context of blood transfusion microbiology. Currently 
virologists have access to a wide range of markers for 
hepatitis B virus infection and its associated disease. 
There is also much data available worldwide on the 
epidemiology of the virus and its transmission in various 
populations. However, even at this stage the picture is not 
totally complete. To gain an understanding of the carrier 
state in U.K. blood donors, we need an analysis of 
available data which can be put to both practical and 
epidemiological use. The information becomes particularly 
relevant in the field of donor counselling for reassuring 
the donor and forecasting what will happen to him in the 
future.
i
The data considered here contributes to our detailed 
understanding of the epidemiology of the hepatitis B virus 
iii individual donors and also gives an insight into the 
situation of the British blood donor population as a 
whole. However, we are not seeing the situation as 
reflected in the 'normal' population, since blood donors at 
NLBTÇ are between the ages of 18 and 70 years of age and 
expected to be in good health. Potential donors who may 
fall into so-called "high-risk" groups such as intravenous 
drug users or homosexuals/bisexuals and their sexual
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contacts and anyone who has had sex with a prostitute or 
anyone from a known high-risk area are asked not to give 
blood.
Investigation of test procedures.
It is of limited value to report only a "positive" or 
"negative" scoring of an HBsAg test for the safe release of 
blood and I wished to examine the various viral markers 
quantitatively in order to monitor changes in levels of 
HBsAg with time in our donor population. This study is the 
first stage in providing some data on this topic. In the 
first instance it was necessary to define the assays to be 
used, and to provide data on their precision , the spread 
of results and variations within assays on different days 
when using different batches of reagents and between 
different operators.
For example, in the case of the reverse passive 
haemagglutinatioh assay, a series of end-point titrations 
were performed by two different operators on two different 
days using different batches of reagents. The results shown 
in figures 16-19 show that there was small variation 
between operators and batches: i.e. a CV between 5.1% and 
8.7%. It was observed however, that a variation in titre of 
only one dilution resulted in a variation by a factor of 
one power of 2, since titres of virus obtained in this way 
are logarithmic. Although this is generally considered 
acceptable, it may result in rather a distorted picture in 
terms of the precision required when studying changes in
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titre. The haemagglutination assay can be made more 
accurate if dilutions are made in smaller steps, however 
the advantage of an EIA or RIA is that there is a 
dose/response relationship over a given area of the 
calibration curve. I therefore realised that any future 
quantitation studies would need to be performed by the use 
of either an EIA or a SPRIA when direct reference can be 
made to a calibration curve of known standards in terms of 
nanograms of HBsAg per ml of serum. (See figure 27.)
Quantitation systems.
Theoretically there should be a simple linear relationship 
between counts per minute, optical density or fluorescence 
and antigen concentration. As this is the exception rather 
than the rule, where suitable reference preparations are 
available the concentrations can be extrapolated from a 
standard curve.
The basic assumption underlying the use of a standard to 
quantitate antigen in an immunoassay is that analytes in 
the standard and test specimens exhibit the same ability to 
bind at the solid-phase receptor sites. Ideally they should 
be identical in molecular configuration. Additionally the 
diluent, which is selected for the reference preparation 
should closely resemble the sample. This can be difficult 
to achieve for all test samples due to normal variation in 
the constituents of serum. These differences can give rise 
to non-specific effects that alter the kinetics of the 
antigen-antibody reaction and can result in artifacts such
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as non-specific binding or differential binding plateaux. 
However, it is not possible to tailor a reference 
preparation to each serum sample.
i
À parallelism study is useful for identifying and 
monitoring any changes in the assay performance. Ideally 
the standard and test specimens should exhibit parallel 
dilution curves. The practical importance of this is that 
if any test sample dilution is analysed, it will generate 
the same final dose estimate after interpolation from the 
standard curve, following correction for specimen dilution.
Heterologous interpolation is the method of choice where it 
is not possible to include a homologous reference serum for 
each specimen. A heterologous standard contains a known 
amount of analyte similar to the one being measured in the 
assay. The major requirement is that the dilution curves of 
the test sera and heterologous standard are parallel, to 
ensure that.the interpolated dose is the same no matter 
what dilution is analysed. The results can be reported in 
weight per volume e.g. ng/ml.
In future studies, in order to examine the long-term 
kinetics of HBsAg carriage, I hope to initialise a 
quantitation system within the laboratory which will enable
i
me to reassess the levels of HBsAg in our carrier 
population with a much greater degree of precision than 
that presently employed, i.e. the Wellcome Hepatest assay.
I should also like to re-establish subtyping of our donors 
as this was abandoned sometime in the early eighties. I
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could therefore examine our donor population and test 
whether or not the ad subtype is still predominant. This 
would also help to complete the data which is at present 
lacking. In addition I should like to examine tests for the 
detection of viral DNA such as PCR and DNA hybridisation 
assays as an aid to infactivity studies.
Data were initially collected for the assays which were 
currently in use for HBsAg testing at NLBTC at the time I 
began this study, that is for RPHA and for SPRIA. During 
the study changes were made in procedures and the current 
HBsAg assay is now EIA, therefore I include a brief 
characterisation of this assay in appendix 3. There is also 
an evaluation of this assay in the section on test 
evaluations. (See figure 29).
Preliminary analysis of accumulated data.
My main topic of investigation was an analysis of the 
accumulated data on the HBsAg-positive donor population at 
NLBTC where we have a unique collection of donor follow-up 
data gathered over a period of 18 or more years. This has 
received only cursory comment and analysis hitherto.
However there are potentially a large number of parameters 
for analysis, and for the purposes of this study it was 
necessary to concentrate on only some of these.
In September 1983 the first DHSS leaflet on AIDS in 
relation to blood donors was made available to blood 
donors. Throughout 1984 the level of AIDS education for
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donors was stepped up. The aim was to specify those areas 
of "risk" behaviour for donors and to ask them not to 
attend if they had engaged in such behaviour. We predicted 
that this would also have an effect on the numbers of cases 
of HBV that we saw, and it did, (see figure 30.) presumably 
because 'at-risk' donors ceased to donate blood. Since HBV 
shares several routes of infection with HIV, (both are 
transmitted sexually and by intravenous drug abuse), donor 
"self-exclusion" due to AIDS education resulted in a 
dramatic fall in the rate of HBsAg positivity in donors 
subsequent to the introduction of measures to prevent HIV 
transmission by transfusion.
Prior to 1985, approximately half of our HBsAg-positive 
donors were from high-hepatitis-risk areas and half were 
native-born Britons. Most of these native-born 
HBsAg-positive donors were white, male and homosexual. 
Following the introduction of AIDS education, our HBsAg. 
prevalence halved (see figure 30.). Overall, prior to 1984, 
15% of all our HBsAg positive donors were undergoing an 
acute infection. Because half of all HBsAg positive donors 
were white, and most of the acute infections were in white 
donors, 30% of white,HBsAg-positive donors were undergoing 
an acute infection and a large proportion of the rest were 
HBeAg positive (i.e. recent) carriers. Subsequently, the 
number of acute HBV infections in our donors has dropped 
drastically, from 0.004% in 1984 to 0.00% in 1989 rising 
slightly to 0.0015% in 1990.(See figures 30 and 31).
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If we did not differentiate between the acute and chronic 
infections then we would not see the full pattern of 
infection.in the different donor populations. In the 
western world, acute HBV infections occur most commonly 
because of intravenous drug abuse and male homosexuality 
with some transmission from males to females; in contrast, 
the carrier state in high prevalence areas is most commonly 
seen as a result of vertical (mother to baby) transmission.
The majority of HBsAg positive donors are detected in the 
'new donor' population because they have not been tested 
previously. If HBsAg is detected in a previously tested 
donor, it usually reflects acute infection, other possible 
reasons are changes to tests leading to increased 
sensitivity or very rarely, technical errors causing missed 
positives. From the data included in this study I can 
confirm the findings of others that infection is more 
likely to occur in males (Gerety 1985) as 89.4% of acute 
infections and 70.8% of carriers in my population sample 
were male. I can also confirm that carriers are more likely 
to come from tropical or mediterranean areas, (Barbara 
1983) as 41.8% of carriers were born outside the U.K. and 
only 14.8% of acute infections were born outside the U.K.
Donors from high-hepatitis-risk areas constitute less than 
2% of our donor population and therefore exert a 
disproportionate effect on our HBsAg positive rate with 
respect to their small numbers. Most of the other published 
work refers to studies done before the advent of HIV 
infection; post-AIDS, if anything, this effect is
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heightened because of the self exclusion of homosexuals and 
intravenous drug abusers and also because of our 
encouragement to the ethnic minorities to donate blood to 
serve our current patient population, which includes large 
numbers of these ethnic minorities needing supplies of the 
rarer (to the U.K.) blood groups.
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Duration of infection and the carrier state.
When counselling donors who are HBeAg positive it is 
necessary for their peace of mind to be able to predict to 
some extent how long they are going to be infectious 
because of the need to try to prevent transmission from 
mother to child, sexual transmission and also accidental 
transmission. For this reason a major part of my work has 
been the analysis of HBe antigen and antibody rates. 
Previous findings on percentage HBeAg to anti-HBe 
seroconversion rates cite a 5%-25% per, annum conversion 
rate (Lok et al. 1987.). The data for our 35 HBeAg-positive 
donors was subjected to a Kaplan-Meier analysis which 
produced an estimated lower quartile time to seroconversion 
of 3.83 years and a median seroconversion time of 8.25 
years.(The upper quartile could not be estimated due to 
there being less information available). This corresponds 
to an average rate of 6.5% per annum for the first 25% to 
seroconvert and 5.7% for the next 25%.
Previous estimates have not been made on a comparable basis 
so it is difficult to compare other studies with our own, 
but previous data range from 3% per annum (Viola et al.
1981 U.K.) to 21% per annum (Hoofnagle et al. 1981 U.S.A.). 
Weller et al. 1985(U.K.)state a seroconversion rate of 10% 
per annum using only the HBeAg-positive time of follow-up 
and not the HBeAg-negative period that followed loss of 
HBeAg which falsely lowers the true spontaneous rate of 
loss of HBeAg. Our figure of 5-6% per annum lies at the 
lowest end of the scale probably due to the fact that we
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followed our donors for a much longer period of time and 
also the fact that our donor population have been pre­
selected as fit, healthy individuals between the ages of 18 
and 65 years.
I wanted to undertake a detailed analysis of the length of 
time of HBeAg positivity because of its significance with 
respect to infectivity , i.e. vertical transmission, sexual 
transmission, and "needlestick" (small volume) 
transmission, and also as a prognostic indicator of 
clinical sequelae, as HBeAg is associated with raised ALT 
levels in chronic liver disease. This is of crucial 
significance for the effective counselling of donors 
confirmed to be HBsAg-positive. When a donor is confirmed 
to be HBsAg-positive, we feel it is our duty to provide 
them with the fullest advice possible on the significance 
of our findings and to discuss the significance of these 
findings for the future of the donor. My study has provided 
à sound basis for counselling because it includes the 
detailed follow-up over a long period of time of a large 
number of cases.
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Markers of infectivity.
HBeAgiis commonly considered the most indicative marker of
infectivity because of its high level of correlation with
the presence of replicating virus material. At present we
do not quantitate this marker routinely in our laboratory.
However with the RIA assay which we use, this could be a
possibility. However is is now known that HBeAg and
anti-HBe are not totally reliable as parameters of
viraemia. (Bonino et.al. 1981 and 1986.) As many as 10-15%
of viraemic anti-HBe-positive HBsAg carriers can have more 
5than 10 HBV genomes per ml of serum.
A most important marker of viral replication is viral DNA. 
This can be assayed by either PCR or DNA hybridisation (see 
page 90). Detection of HBV DNA by spot hybridisation 
correlates well with infectivity and the number of genomes 
present. However I am led to conjecture here that if 
ultimate sensitivity of viral replication were required, 
perhaps we should be attempting PCR amplification of the 
RNA pregenome which is transcribed to DNA by reverse 
transcriptase during viral replication. Amplification of 
this RNA would truly reflect active viral replication and 
not simply the presence of non-replicating genomic 
material.I
Another marker of infectivity is DNA polymerase. We do not 
test for this marker at present as there are more important
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markers of infectivity for which senstive screening tests 
are available.
Infectivity in blood donors.
in carriers (defined formally as carriage of HBsAg for 6 
months or more), of the 12.28% who were HBeAg positive, 
77.14% maintained their HBsAg positivity throughout their 
follow up period (mean 4.25 years). 22.9% of those donors 
found positive for HBeAg, subsequently went on to develop 
anti-HBe during the course of their period of follow-up, 
giving a 5% per annum seroconversion rate. Since our HBeAg 
longevity data is based on long-term, detailed follow-up on 
a relatively large number of donors it is likely to be 
accurate. We have seen that there is variation in HBeAg 
longevity in carriers but close analysis concurs with that 
of other researchers studying patients in Sexually 
Transmitted Disease clinics etc. That is, that some 
carriers maintain HBeAg for very long periods of time ( see 
figure 34. donor no. 265, still maintaining HBeAg after 14 
years of follow-up) and that on average 5-25% per annum 
seroconvert to anti-HBe.
Stability of titre.
The longevity of surface antigen carriage is to be the 
subject of future research, but our preliminary data showed 
that 54.7% maintained stability of titre throughout the 
period of follow-up, with 18.2% falling by three dilutions
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or more and 27.4% falling by less than three dilutions 
during their period of follow-up (mea# 4.82 yrs.).
Many centres still persist in calling HBsAg positive donors 
"carriers" without a full characterisation of those markers 
which confirm the carrier state, that is anti-HBc IgM, and 
parallel titrations of HBsAg in the serum, often these are 
not real carriers.
j .
The association between a rise in liver function test 
levels and HBeAg positivity demonstrated by Barbara,
Mijovic et al. (1978). was corroborated by continual 
follow-up data in my study in that out of 27 HBeAg-positive 
donors, an initial rise in LFT levels was observed in 17 
(62.96%) and a subsequent rise in 4 (14.8%), whilst normal 
LFTs were observed in 107 out of 164 anti-HBe positive 
carriers (65%). Also, in the 8 donors who eventually 
seroconverted from HBeAg, elevated LFT values were seen in 
5 of these, with normal LFT values eventually restored in 
the three who were monitored continually for some time 
following their seroconversion. Therefore the conclusion 
drawn from this data is that approximately 5% per annum of 
donors positive for HBeAg will go on to seroconvert to 
anti-HBe with the associated reduced infectivity risks and 
better prognosis for their long-term health and well-being. 
This information can give considerable reassurance to 
donors during counselling.
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A glimpse of the future.
Data collected at one centre over many years can have 
considerable potential value for the epidemiologist. Take 
for example the recently-cloned hepatitis C virus ; unlike 
HBV, which has been studied since the 1960s, our 
understanding of HCV is in an early phase, 
epidemiologically speaking. At this stage we do not know 
which antibody-positive donors are really infectious and so 
we have to assume all are. We do not know if there are 
different levels of infectivity and we do not know how the 
virus spreads in nature. However with HBV we now know that 
there is less chance of natural infectivity from blood or 
sexual contact from an anti-HBe positive donor than with 
blood from a donor positive for HBeAg. We know that HBV 
spreads via blood and semen. This results in potential 
transmission by sexual contact and intravenous drug abuse 
and also in certain institutions such as mental hospitals 
where residents may cause each other subcutaneous injuries 
by scratching or biting.
Clearly, the more complete our understanding of the 
mechanisms of transmission and the duration of infectivity, 
the greater our chance of reducing the risks. The field of 
transfusion microbiology is constantly changing and rapidly 
responding to changing requirements (see section 2).During 
the course of this study at NLBTC we have been faced with 
the evaluation and implementation of a new and different 
form of assay for the routine testing of blood donations 
for the HBV marker, hepatitis B surface antigen, we have
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now changed from a SPRIA to an EIA assay. Today we also 
face the challenges of adjusting to laboratory automation 
and information transfer. Detailed study of epidemiology 
of HBV markers should help us to optimise the strategy used 
to provide a safer product. Soon we may be asked to begin 
testing for another HBV marker, anti-HBc, and the need to . 
test routinely for this marker is currently under debate.
If implemented, this assay will provide an even greater 
level of sensitivity in HBV testing, since donors with 
anti-HBc as the only marker of infectivity (with subliminal 
levels of HBsAg) have been shown to transmit 
post-transfusion HBV, which can be fatal in the 
immunosuppressed patient.
My study illustrates the range of data that can be 
accumulated by follow-up of donors found to be carrying 
HBsAg. It serves as a base line for further work to examine 
such donors in more detail, thus providing a better overall 
understanding of the carrier phenomenon. The same approach 
would be useful to the follow-up of donors with other 
persistent infections with viruses such as HCV,
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APPENDICES; SUMMARIES OF PROTOCOLS OF ASSAYS USED IN 
PROVIDING THE EXPERIMENTAL DATA.
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Appendix 1; Solid Phase Immunoradiometric Assay for 
Hepatitis B Surface Antigen Detection.
Reagents used in this study are supplied by the Blood 
Products Laboratory (BPL) Elstree.
j(a) Anti-HBs Immunoglobulin for Coating of 
Microwells.
High-titre anti-HBs serum from immunised horses is 
heat-inactivated at 56°C for 30 mins. and then absorbed 
for anti-human antibodies by passage through affinity 
columns. The globulins are precipitated in 40% 
saturated(NH^)2S0^ at 4°C, redissolved in Tris/Az 
containing 0.9% NaCl to the original volume (Tris/Sal/Az) 
and dialysed against Tris/Sal/Az.
(b)125 i_iabelled anti-HBs.
Purified anti-HBs from heat-inactivated goat anti-serum is 
iodinated (Cameron et al. 1980).
The labelled antibody is diluted to a count of 
25 nanp-curies (nCi) per 0.1 ml in Tris/Az containing 10% 
normal human serum (NHS), 6% normal horse serum and 4% 
normal goat serum. The diluted labelled antibody gives a 
radioactive count of approximately 40,000 c.p.m. per 0.1 
ml.
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(c) Positive Control Serum.
Positive control serum is obtained from a single high titre 
HBsAg positive donor and diluted to levels of 20ng/ml, 
4ng/ml, Ing/ml, 0.25ng/ml,and O.lng/ml in NHS containing 
0.1% sodium azide.
(dj Negative Control Serum.
Negative control serum is from a pool of normal human serum 
found negative by radioimmunoassay for HBsAg, anti-HBs and 
anti-HBc, and contains 0.1% sodium azide.
(e) 0.02M Tris/HCL Buffer with 0.1% Sodium Azide.
This is prepared in the laboratory as follows:
Dissolve : Tris(hydroxymethyl)methylamine 12.114g
in 1 litre deionised water
Add : Sodium Azide 5.0g
5M HCl 13.75ml
The final volume is adjusted to 5 litres with deionised 
water. The final pH should be 7.6., this is adjusted by the 
addition of HCL.
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The principle of this assay is that of the labelled 
antibody "sandwich" type of immunoassay illustrated in 
Section 3, figure 12 (E).
Test Procédure.
0.1 ml of serum or plasma is incubated in the antibody 
coated wells in a waterbath at 45°C for 90 mins. The 
wells are then washed five times in de-ionised water. 0.1 
ml of radiolabelled antibody is then added to each well. 
The wells are incubated as before in the 40°C waterbath 
for a further 90 mins. They are then re-washed as before 
and counted in a gamma counter. The counts per minute can 
be compared with a set of known standard negatives from 
BPL, but calculation of the cut-off is performed by 
computer.
À mean and standard deviation is calculated for all wells 
with a count less than 100 c.p.m. All results within the 
mean plus or minus 3 standard deviations are used to 
calculate a new mean and standard deviation. A result is 
deemed positive if it is greater than the new mean plus 3 
standard deviations.
If for any reason the computer is non-functional the 
cut-off can be calculated from the raw data by taking the 
mean of a random sample of negatives and multiplying this 
by 1.5.
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Appendix 2s Reverse Passive Haemaaalutination Assay (RPHA^
The principle of the test is that the reagent red blood 
cells have been treated with tannic acid, purified horse 
anti-HBs can then attach to produce "sensitised" cells 
which will agglutinate in the presence of HBsAg. So that 
non-specific reactions may be detected, "control" cells 
coated with pre-immune normal horse immunoglobulin are also 
used. Both test and control cells have been treated with 
formalin and freeze-dried for stability on storage.
Reagents.
(a) Test Cells.
These consist of a freeze-dried 1% suspension of aldehyde 
treated, tanned turkey red blood cells coated with purified 
horse anti-HBsAg in phosphate buffered saline (pH 7.2) 
containing 5% sucrose,1.5% normal rabbit serum and 0.01% 
thiomersal.
(b) Control Cells.
i
These consist of a freeze-dried 1% suspension of aldehyde 
treated, tanned turkey red blood cells coated with normal 
horse globulin,in phosphate buffered saline (pH 7.2) 
containing 5% sucrose 1.5% normal rabbit serum and 0.01% 
thiomersal.
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(c) Diluent Buffer.
Phosphate buffered saline (pH 7.2) containing normal human 
serum, normal turkey serum and 0.1% sodium azide. The 
volumes of normal sera are adjusted to give the optimal 
results for each batch of sensitised cells hence the need 
to use a complete set of matched reagents.
(d) Positive Control.
Diluted human serum inactivated by heating at 60°C for at 
least 10 hours. When tested at a 1:8 dilution, the positive 
control should give a clear agglutinated pattern with the 
test cells. When fully titrated the end-point should be not 
less than 1:32 against test cells, while the control cells 
should show unagglutinated patterns at all dilutions. 
Failure to comply with all of the above conditions 
indicates deterioration of either test or control cells or 
contamination of diluent buffer.
(e) Negative Control.
Normal human serum. No agglutination should be observed 
with either test or control cells. Failure to comply is 
indicative of deterioration of test or control cells or 
contamination of diluent buffer. Both negative and positive 
control sera contain 0.1% sodium azide.
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Test Procedure.
Quantitative Test.
Method.
Using a standard 25 microlitre dropper, one drop (0.025 ml) 
of diluent is placed in each well of a "U"-well microtitre 
plate. Two rows of wells are used for each sample to be 
titrated. The first row is used to demonstrate the reaction 
with the test cells,and the second to demonstrate the 
reaction with the control cells.
0.025 ml of serum is added to the first well of both test 
and control rows with a micropipette or microdiluter. Serum 
and diluent are carefully mixed and 0.025 ml of the mixture 
is transferred to the next well of each row, giving a 
dilution of 1:4. This procedure is repeated for each well 
of the two rows to give serial dilutions from 1:2 to 1:256.
Using a 0.025 ml dropper, one drop of reconstituted test 
cells is added to each well of the test row, starting with 
the 1:2 dilution.
One drop of reconstituted control cells is similarly added 
to the control row . The plate is then tapped on all four 
sides to mix the reagents thoroughly.
The plate is then covered with a lid and allowed to settle 
on a flat surface away from vibration or direct sunlight.
184
Interpretation of results.
The end-point is taken as the highest dilution showing 
definite signs of agglutination, judged by the size and 
appearance of the ring.
A positive result for HBsAg is indicated by the presence of 
at least a fourfold greater titre in the test row than in 
the control row. Agglutination in the control row to within 
one well of. the test row indicates a non-specific reaction. 
Full confirmation should always be obtained in 
haemagglutination test by the use of specific 
neutralisation tests however, or by the use of alternative 
procedures of equal or greater sensitivity such as SPRIA or 
ELISA techniques.
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Plate 5 . Microtitration plate showing Wellcome Hepatest 
with positive control wells Al. Bl. A2. B2.
Appendix 3; Bioelisa EIA for HBsAa.
The reagents are supplied by Launch Diagnostics and are 
manufactured by Biokit S.A. in Barcelona, Spain.
At NLBTC we use a shortened protocol involving the use of a 
shaker incubator for the sample and conjugate stages of 
incubation to ensure adequate sensitivity whilst keeping 
incubation time to a minimum.
i
Bioelisa is a direct immunoenzymatic method of the 
"sandwich" type, in which guinea-pig anti-HBs coated on to 
microtitre plate wells acts as the capture antibody. Goat 
anti-HBs marked with peroxidase serves as the conjugate.
Test procedure.
0.1 ml of the serum samples and positive and negative 
controls are incubated in the antibody-coated wells. If the 
sample contains HBsAg, the antigen will bind to the 
antibody on the plate. After washing to eliminate any 
unbound material, 0.1 ml of goat anti-HBs conjugate is 
added to the wells and allowed to react with the 
antigen-antibody complex formed in the first incubation. 
After this second incubation and subsequent washing an 
enzyme substrate (hydrogen peroxide) solution containing 
TMB chromogen is added. This substrate (hydrogen peroxide) 
will develop colour if the sample is HBsAg positive. The 
intensity of the colour is proportional to the amount of 
HBsAg in the test specimens. The reaction is stopped by the
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addition of 0.1 ml of 2M HgSO^. The colour intensity is 
read in a spectrophotometer at dual wavelengths of 450 and 
620 nm respectively.
In our hands this shaking incubation procedure is sensitive 
to a level of approximately 0.2 ng of HBsAg per ml of 
serum.
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Appendix 4; Specific Neutralisation Techniques.
(i) SPRIA.
Samples giving a repeatable positive screen test can be 
confirmed by performing a specific neutralisation test 
using normal and immune human, rabbit and horse sera.
The test is performed by setting up six tests pairing 
normal and immune sera in the proportions 0.1 ml test serum 
with 0.02 ml normal or immune serum in the same well and 
then proceed as for the normal screen test.
Specific neutralisation is confirmed when the count for the 
immune serum is at least half the count for the normal 
serum. With a very strong positive serum it may be 
necessary to perform the neutralisation test on a suitable 
dilution to avoid the immune serum being overpowered by 
large amounts of viral antigen.(Cameron,C.H. and Briggs,m. 
J.Virol. Meth. 1980 1 113-116)
This method can also be used to attempt specific 
neutralisation using the Bioelisa HBsAg EIA assay except 
that the origin of thé immune sera is human, from two 
high-titre anti-HBs positive donors, rather than horse or 
rabbit as for SPRIA. Reduction in optical density of 50% or 
more indicates a successful neutralisation. If required the 
anti-sera may be allowed to react for 20 mins in a test 
tube with the reactive sera before the test is performed.
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(ii) RPHA
When a HBsAg titre has been obtained by the standard 
Hepatest method a specific neutralisation test can be 
carried out to confirm the positive result.
The test is performed in triplicate on a suitable dilution 
of the serum. Standard titrations are made in three rows of 
the microtitre plate and 0.025 ml of normal and immune 
horse serum are added to the three wells before the known 
end-point, test cells are added to the first two rows and 
control cells to the third row :
Neutralisation Well 1 2  3
Row 1 Immune serum + test cells
Row 2 + + + Normal serum + test cells
Row 3 Normal serum + control cells
Neutralisation is confirmed if the above pattern is seen 
where the positive reaction is neutralised by the immune 
serum but the positive reaction is still observed with the 
normal serum.
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Appendix 5; Monoclonal Radio-Immunoassay fRIAï for 
HBeAg/Ab.
The reagents are supplied by the Department of Virology, 
Middlesex Hospital Medical School and are used routinely at 
NLBTC on all HBsAg-positive serum samples.
(i) The principle of the test is similar to that described 
for SPRIA for HBsAg except that HBeAg is added to the 
antibddy-coated wells on top of the test serum so that 
anti-HBe-positive serum will neutralise the antigen 
resulting in detection of low levels of bound radiolabel, 
HBeAg-positive serum will yield very high .
counts-per-minute, whilst the negative range, where neither 
antigen nor antibody are detectable, lies somewhere in the 
middle of the two. Test results are compared with a series 
of known HBeAg, anti-HBe and negative control sera included 
on each test plate.
(ii) Reagents.
(a) Anti-HBe Immunoglobulin-Coated Microwells.
"Removastrip" microwells are coated over three days with a 
mixture of monoclonal e6 and e9 gammaglobulin 
precipitates, diluted 1 in 2000 in 0.02M Tris/Azide to 
give a total globulin concentration of 1 in 1000. The wells 
are then quenched with 0.2% bovine serum albumin (BSA) and 
stored at 4°C.
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(b) Controls.
Positive control serum consists of known HBeAg-positive 
donor serum diluted to 1 in 1000 in normal human serum 
(NHS). Negative control serum consists of a pool of known 
anti-HBe-positive sera diluted to 1 in 3000 in NHS. 
Negative control serum consists of. pooled NHS.
(c) Radiolabel.
125This consists of I-labelled e2 gammaglobulin diluted 
in "e diluent" to give approximately 400,000 counts-per-10 
minutes.
(d) "e Diluent".
This is made in the laboratory as follows:
Bovine serum albumin..................... .. 2 %
Normal human serum.........................4%
in 0.02M Tris
Test Procedure.
0.05 ml of sample and controls are added to the coated
wells 0.05 ml of HBeAg control is then added to all wells
including both samples and controls. These wells are 
incubated overnight at room temperature with a cover over 
the plate. The wells are washed five times in de-ionised
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water and then 0.1 ml of radiolabelled antibody is added to
i
each one. The wells are then incubated for 2-4 hours at 
room temperature and then washed again in de-ionised water. 
The wells are then counted in a gamma counter.
The results are then evaluated by a computer. The 
"cut-offs" are calculated as follows; any result greater 
than or equal to the mean of the four HBeAg controls is 
HBeAg positive, any result equal to or less than the mean 
of the four anti-HBe controls is anti-HBe positive. Any 
result falling between the means of both these controls is 
said to have neither HBeAg nor anti-HBe detectable.
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Appendix 6; Estimation of Serum alanine 
aminotransferase(ALT)
and Serum aspartate transaminase (ASTÏ
The test is performed in the biochemistry department at 
NLBTC using reagents supplied by Diagnostics Merck 
(F.R.Germany), using the Eppendorf Epos Analyzer at 37®C
(i) The principle of the test is as follows:
(a) AST
HOgC-CHg-CHfNHgl-COgH + HOgC-fCHgig-CO-COgH
L-aspartate 2-oxoglutarate
AST J r
HOgC-CHg-CO-COgH + COgH-tCHgjg-CHfNHgi-COgH
oxalacetate L-glutamate
mDH J C NADH
HOgC-CHg-CHfOHj-COgH + NAD"*"
L-malate
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(b) ALT
HgC-CHgfNHgl-COgH + HOgC-fCHgig-COgH
L-alanine 2-oxoglutarate
ALT j f
HgC-CO-COgH + HOgC-fCHgjg-CHfNHgj-COgH 
Pyruvate L-glutamate.
LDH J '[ NADH
HgC-CHfOH)-CO2H+NAD+
L-lactate
The rate of decrease in absorbance at 340nm is directly 
proportional to the concentration of AST or ALT in the 
serum sample.
Normal ranges;
AST ALT
male 4-45 iu/1 4-52 iu/1
female 4-30 iu/1 4-29 iu/l
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Test Procedure.
Merkotest A reagents supplied by BDH are used in 
conjunction with the Eppendorf Epos Analyzer 5060 to 
photometrically determine the concentrations of ALT and AST 
in serum samples .
Reagent 1 for both assays is prepared by emptying the 
appropriate substrate solution (L-alahine for ALT, 
L-aspartate for AST) into the corresponding NADH enzyme 
mixture. After standing for 10 minutes, solution is 
assisted by gentle mixing.
Reagent 2 (2-oxoglutarate solution) is the same for both 
assays and requires no preparation.
The R1 cup (maximum volume 80cm^) is filled with reagent 
1 and placed in position on the Epos, (see diagram).
The R1 cover is prepared by filling Cl with internal 
control serum and C2 with Wellcome control serum. Cleaner 
solution (BDH) is placed in the well provided and the cover 
secured with clear film. It is locked into position on the 
R1 cup.
Reagent 2 is poured into the R2 container and placed in 
position on the Epos.
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The appropriate assay is selected and the required 
information entered. The Epos will perform the assay giving 
a printout of results. Any samples with enzyme values too 
high to be measured wil be automatically diluted and 
remeasured by the machine.
Any results which are outside the normal assay range may be 
repeated.
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Figure 45.
The EPOS analyser.
Appendix 7; Reverse passive haemaaalutination test for 
alpha-foetoorotein.
The reagents are manufactured by Fujizoki of Japan.. Fixed 
chicken erythrocytes sensitized with mouse monoclonal 
anti-AFP antibody are agglutinated in the presence of AFP 
in serum, plasma or ascites.
Test procedure.
2 drops (0.05 ml) of absorbing diluent are placed in each 
well of row 1, and 1 drop (0.025 ml) in each of wells 2 to 
12 of a microtitration plate, using a calibrated pipette 
dropper.
5 microlitres of test serum is added to each well of row 1 
using a micropipette.
Doubling dilutions are made from row 1 to row 12 using a 
micropipette.
1 drop (0.025 ml) of control (unsensitised) cells is added 
to each well of row 1 and 1 drop (0.025 ml) of test
i
(sensitised) cells are added to rows 2 to 12 of the 
micrototration plate, using the droppers provided.
The plate is then rotated vigorously for 1 minute and 
incubated horizontally at room temperature for 1 and a half 
hours and read for haemagglutination.
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